Novel compound or salt thereof, catalyst, method of preparing novel compound or salt thereof and method of preparing mannich product

The novel 1,3-diamine derivative catalysts address the underexplored potential of 1,3-diamine derivatives by facilitating efficient Mannich reactions, achieving high enantioselectivity and yield in Mannich product synthesis when used in conjunction with specific acids.

WO2024242204A1PCT designated stage expired Publication Date: 2024-11-28OKINAWA INST OF SCI & TECH SCHOOL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/019308
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-24
Filing Date
2024-05-24
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

1,3-diamine derivatives have not been extensively explored as catalysts despite their potential in chemical transformations, particularly in pharmaceutical applications, and there is a need for novel catalysts that can efficiently facilitate Mannich reactions.

Method used

A novel 1,3-diamine derivative and its salt are developed, which can be used as a catalyst in Mannich reactions, formed by converting an -NHPMP moiety to an amino group through reductive amination and subsequent conversion to a tertiary amino group, and used in conjunction with acids like trifluoroacetic acid and dibenzyl phosphate.

Benefits of technology

The novel 1,3-diamine derivative catalysts demonstrate high enantioselectivity and efficiency in Mannich reactions, enabling the synthesis of Mannich products with high yields and selectivities, and can be used in both pharmaceutical and polymeric material synthesis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024019308_28112024_PF_FP_ABST
    Figure JP2024019308_28112024_PF_FP_ABST
Patent Text Reader

Abstract

Provided is a novel 1,3-diamine derivative and its applications. A compound represented by a formula (I) or a salt thereof.
Need to check novelty before this filing date? Find Prior Art

Description

NOVEL COMPOUND OR SALT THEREOF, CATALYST, METHOD OF PREPARING NOVEL COMPOUND OR SALT THEREOF AND METHOD OF PREPARING MANNICH PRODUCT

[0001] The present disclosure relates to a novel compound or salt thereof, a catalyst, a method of preparing a novel compound or salt thereof, and a method of preparing a Mannich product.Background

[0002] Amine derivatives have been used as catalysts and components of catalyst systems to accelerate chemical transformations. For example, compounds that have a primary amine group and a tertiary amine group in a geminal relationship (or 1,2-relationship), such as cinchona-derived amines, cyclohexane-1,2-diamines, and 1,2-diarylethane-1,2-diamines, for example, the following compounds: have been used as catalysts with or without other molecules (such as acids) to accelerate bond-forming reactions of enolizable ketones and aldehydes as nucleophiles.

[0003] Whereas 1,2-diamine derivatives have been extensively explored as catalysts, 1,3-diamine derivatives have not been popularly examined as catalysts. For pharmaceutical applications, propane-1,3-diamine derivatives with specific chemical structures have been proposed (PTL 1). The propane-1,3-diamine derivatives have a disubstituted amino group on the carbon to which the aryl group is attached. Other compounds with such amino group have been reported in NPTL 1.

[0004] Further, the propane-1,3-diamine derivatives having a monosubstituted amino group on the carbon to which the aryl group is attached have also been reported (NPTLs 2-4). The monosubstituted amino group has a substituent such as tosyl group, and methane sulfonate group.

[0005] PTL 1: JP2005-50330A

[0006] NPTL 1: B Meria, et al. “A simple and Highly Diastereoselective one-Pot Synthesis of 1,3-Diamines”, Synlett 1997, p.177-178 NPTL 2: T. Kashiwagi, et al., “Diastereoselective synthesis of 1,3-diamines by a domino reaction of imines, enamines, and trichlorosilane”, Tetrahedron Lett. 2014, 55, p. 1924-1926. NPTL. 3: M. Ito, et al. “Imino ene-type reaction of enamines with N-sulfonylimines and application to diastereoselective synthesis of N-sulfonyl-1,3-diamines”, Tetrahedron Lett. 2014, 55, p.4082-4085. NPTL. 4: M. Sugiura, et al. “Stereoselective Synthesis of Nitrogen-Containing Compounds from Enamines”, J. Org. Chem. 2017, 82, pp. 10968-10979.Summary

[0007] A novel 1,3-diamine derivative and its application are expected to be developed.

[0008] An object of this disclosure is to provide a novel 1,3-diamine derivative and its applications.

[0009] The gist of the present disclosure is as follows: [1] A compound represented by a formula (I) or a salt thereof wherein R1and R2are independently selected from the group consisting of an alkyl, an alkenyl, an alkynyl, a heteroalkyl, a heteroalkenyl, or a heteroalkynyl, which may be substituted with one or more selected from the group consisting of an aryl and a heteroaryl, or R1and R2together form - (CH2)p-, and the - (CH2)p- forms a ring in combination with the nitrogen atom that the R1and the R2are both attached to, wherein p is an integer from 2 to 8, and the - (CH2)p- may be interrupted by one to three hetero atom(s) and may be substituted with one or more selected from the group consisting of an alkyl, an aryl, and a heteroaryl; R3is independently selected from the group consisting of an alkyl, and an aryl, or two adjacent R3s may form a ring with carbon atoms they are attached to; R4is independently selected from the group consisting of a halogen atom, an alkyl, an alkoxy, a cyano, a nitro, and an acylamido, or two adjacent R4s may form a ring in combination with carbon atoms they are attached to; m is an integer from 0 to 8; and n is an integer from 0 to 5. [2] The compound or the salt thereof according to [1], wherein the compound is represented by formula (1-1) or (1-2) wherein R1, R2, R3, R4, m, and n are as defined in [1]. [3] A catalyst comprising a compound or a salt thereof according to [1] or [2]. [4] The catalyst according to [3] wherein it is used in a Mannich reaction. [5] A method of preparing a compound or a salt thereof according to [1] comprising: converting an -NHPMP moiety of a compound represented by a formula (II) to an amino group; and introducing the amino group by reductive amination of a carbonyl group of the compound represented by the formula (II), followed by converting the introduced amino group to a tertiary amino group to form an -NR1R2moiety, wherein R1, and R2are as defined in [1]. wherein PMP is a p-methoxyphenyl group, and R3, R4, m, and n are as defined in [1]. [6] A method of preparing a Mannich product, comprising: reacting a compound represented by formula (VIII) with a compound represented by formula (VII), in the presence of a compound represented by the formula (I) according to [1] wherein Rcis a hydrogen atom or a monovalent hydrocarbon group which may be substituted with a -P(=O)(ORd)(ORe), a -C(=O)Rd, a -S(=O)2Rd, a -C(=O)ORd, or a -C(=O)NRfRg, wherein Rdis an alkyl, Reis an alkyl, Rfis a hydrogen atom or an alkyl, and Rgis a hydrogen atom or an alkyl; wherein Rais independently selected from the group consisting of an alkyl, a halogen atom, an alkoxy, and a nitro, or two adjacent Ras may form a ring in combination with carbon atoms they are attached to; s is an integer of 0 to 4; and Rbis a hydrogen atom or an alkoxycarbonyl. [7] The method of preparing a Mannich product according to [6], comprising: reacting the compound represented by the formula (VIII) with the compound represented by the formula (VII), in the presence of the compound represented by the formula (1-1) according to [2] to obtain a compound represented by formula (9-1), or in the presence of the compound represented by the formula (1-2) according to [2] to obtain a compound represented by formula (9-2) wherein Ra, Rb, Rcand s are as defined in [6]. [8] The method of preparing a Mannich product according to [6], comprising: reacting the compound represented by the formula (VIII) with the compound represented by the formula (VII’) to obtain a compound represented by formula (9-3) wherein Rhis a hydrogen atom, a -P(=O)(ORd)(ORe), a -C(=O)Rd, a -S(=O)2Rd, a -C(=O)ORd, a -C(=O)NRfRg, or a monovalent hydrocarbon group which may be substituted with a -P(=O)(ORd)(ORe), a -C(=O)Rd, a -S(=O)2Rd, a -C(=O)ORd, or a -C(=O)NRfRg, wherein Rd, Re, Rf, and Rgare as defined in [6]; wherein Ra, Rb, and s are as defined in [6]; and Rhis as defined in the above.Advantageous Effect

[0010] According to the present disclosure, novel 1,3-diamine derivatives and their applications, including catalytic uses, are provided.

[0011] In the accompanying drawings: FIG.1: The X-ray crystal structure of compound 1a・CF3COOH. FIG.2: The X-ray crystal structure of compound 1g・CF3COOH. FIG.3: The X-ray crystal structure of compound 9g.DETAILED DESCRIPTION

[0012] The presently disclosed techniques will be described in detail below.

[0013] <Terms> (monovalent hydrocarbon group) The term “monovalent hydrocarbon group” refers to a monovalent group consisting of carbon atom(s) and hydrogen(s). Examples of the monovalent hydrocarbon group include, without limitation, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, aralkyl. (alkyl) The term “alkyl” refers to a straight-chain or branched saturated hydrocarbon group. The alkyl preferably has from 1 to 12 carbon atoms (C1-12alkyl), more preferably from 1 to 8 carbon atoms (C1-8alkyl). Examples of the alkyl include, without limitation, methyl, ethyl, propyl (e.g., n-propyl, isopropyl), butyl (e.g., n-butyl, tert-butyl, sec-butyl, iso-butyl), pentyl (e.g., n-pentyl, 3-pentanyl, amyl, neopentyl, 3-methyl-2-butanyl, tertiary amyl), and hexyl (e.g., n-hexyl, ethylhexyl), heptyl (e.g., n-heptyl), octyl (e.g., n-octyl), nonyl (e.g., n-nonyl), decyl (e.g., n-decyl), undecyl (e.g., n-undecyl), and dodecyl (e.g., n-dodecyl). Among the above, the alkyl is preferably methyl, ethyl, or propyl. (alkenyl) The term “alkenyl” refers to a straight-chain or branched unsaturated hydrocarbon group having one or more carbon-carbon double bonds (e.g., 1, 2, 3, or 4 double bonds). The one or more carbon-carbon double bonds can be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl). The alkenyl preferably has from 2 to 12 carbon atoms (C2-12alkenyl), more preferably from 2 to 8 carbon atoms (C2-8alkenyl). Examples of the alkenyl include, without limitation, ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, butadienyl, pentenyl, pentadienyl, hexenyl, heptenyl, octenyl, octatrienyl, nonenyl, and decenyl. Among the above, the alkenyl is preferably ethenyl, 1-propenyl, or 1-butenyl. (alkynyl) The term “alkynyl” refers to a straight-chain or branched unsaturated hydrocarbon group having one or more carbon-carbon triple bonds (e.g., 1, 2, 3, or 4 triple bonds) (“C2-10alkynyl”). The one or more carbon-carbon triple bonds can be internal (such as in 2-butynyl) or terminal (such as in 1-butynyl). The alkynyl preferably has from 2 to 12 carbon atoms (C2-12alkynyl), more preferably from 1 to 8 carbon atoms (C1-8alkynyl). Examples of the alkynyl include, without limitation, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, pentynyl, hexynyl, pentynyl, octynyl, nonynyl, and decynyl. Among the above, the alkynyl is preferably ethynyl, 1-propynyl, or 1-butynyl.

[0014] (heteroalkyl) The term “heteroalkyl” refers to an above alkyl group, which further includes at least one heteroatom (e.g., 1, 2, 3, or 4 heteroatoms) selected from oxygen, nitrogen, sulfur within (i.e., inserted between adjacent carbon atoms of) and / or placed at one or more terminal position(s) of the parent chain. (heteroalkenyl) The term “heteroalkenyl” refers to an above alkenyl group, which further includes at least one heteroatom (e.g., 1, 2, 3, or 4 heteroatoms) selected from oxygen, nitrogen, sulfur within (i.e., inserted between adjacent carbon atoms of) and / or placed at one or more terminal position(s) of the parent chain. (heteroalkynyl) The term “heteroalkynyl” refers to an above alkynyl group, which further includes at least one heteroatom (e.g., 1, 2, 3, or 4 heteroatoms) selected from oxygen, nitrogen, sulfur within (i.e., inserted between adjacent carbon atoms of) and / or placed at one or more terminal position(s) of the parent chain.

[0015] (aryl) The term “aryl” refers to a monocyclic or polycyclic group (e.g., bicyclic or tricyclic) having zero heteroatoms provided in the aromatic ring system. The aryl preferably has 6-20 ring carbon atoms in the aromatic ring system (“C6-20aryl”), and more preferably 6-14 ring carbon atoms in the aromatic ring system (“C6-14aryl”). Examples of the aryl include phenyl, naphthyl such as 1-naphthyl and 2-naphthyl, and anthracyl. (heteroaryl) The term “heteroaryl” refers to a monocyclic or polycyclic group (e.g., bicyclic or tricyclic) having 1, 2, 3, or 4 heteroatoms selected from oxygen, nitrogen, sulfur, the remaining ring atoms being carbon provided in the aromatic ring system. The heteroaryl preferably has 5-20 ring atoms, and more preferably 5-14 ring atoms. Examples of the heteroaryl include, without limitation, furyl, thienyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, isoxazolyl, pyrazolyl, pyridyl, pyridazinyl, indolyl, quinolyl, and isoquinolyl.

[0016] (alkoxy) The term “alkoxy” is represented by “R-O- (wherein R is the above alkyl)”. Examples of the alkoxy include, without limitation, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, and tert-butoxy.

[0017] (halogen) The term “halogen” refers to fluorine (fluoro, -F), chlorine (chloro, -Cl), bromine (bromo, -Br), or iodine (iodo, -I).

[0018] <1,3-diamine derivative> The present disclosure is related to a novel 1,3-amine derivative which is a compound represented by a formula (I) and a salt thereof.

[0019] R1and R2may be independently an alkyl, an alkenyl, an alkynyl, a heteroalkyl, a heteroalkenyl, or a heteroalkynyl, preferably, a C1-8alkyl (e.g., a methyl, an ethyl).

[0020] R1and R2may together form - (CH2)p-, and the - (CH2)p- forms a ring in combination with the nitrogen atom that the R1and the R2are both attached to, wherein p is an integer from 2 to 8, preferably an integer from 4 to 8.

[0021] The - (CH2)p- may be interrupted by one to three hetero atom(s) and may be substituted with one or more selected from the group consisting of an alkyl, an aryl, and a heteroaryl.

[0022] Preferably, R1and R2together form - (CH2)p-, wherein p is an integer from 2 to 8, the - (CH2)p- is uninterrupted or interrupted by one or two oxygen atom(s), one or two sulfur atom(s), or one or two nitrogen atom(s). Preferably it is interrupted by one oxygen atom.

[0023] Preferred examples of the rings formed by R1and R2in combination with the nitrogen atom include pyrrolidine, piperidine, azepazine, piperidine, morpholine, and thiomorpholine.

[0024] The subscript “m” is an integer from 0 to 8, preferably an integer from 0 to 4, more preferably from 0 to 2, and further more preferably 0.

[0025] In case where m is an integer from 1 to 8, R3may be an alkyl, or an aryl, and preferably a C1-8alkyl (e.g., a methyl, an ethyl), and a phenyl. In the case where m is an integer from 2 to 8, two adjacent R3s may form a ring with the carbon atoms they are attached to. The ring formed by two adjacent R3s in combination with the carbon atoms may be an aliphatic ring. The number of atoms constituting the ring may be 6 to 20. Preferred examples of the rings include a cyclohexane.

[0026] The subscript “n” is an integer from 0 to 5, preferably an integer from 0 to 2, and more preferably 0 or 1.

[0027] In case where n is an integer from 1 to 5, R4may be a halogen atom, an alkyl, an alkoxy, a cyano, a nitro, and an acylamido, preferably a halogen atom, more preferably a bromine atom. In case where n is an integer from 2 to 4, two adjacent R4s may form a ring with carbon atoms they are attached to. The ring formed by two adjacent R4s in combination with carbon atoms may be an aromatic ring. The number of atoms constituting the ring may be 6 to 20. Preferred examples of the ring include benzene, and piperidine.

[0028] Preferred examples of the compound (I) include a compound represented by a formula (I’). wherein the definitions and examples of R1, R2, and R4are as mentioned above.

[0029] The compound (I) may be in a form of a salt. The salt may be an acid addition salt of an inorganic acid or an organic acid. Examples of the inorganic acid and the organic acid include hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, trifluoroacetic acid, succinic acid, tartaric acid, methane sulfonic acid, and p-toluenesulfonic acid.

[0030] The compound (I) encompasses a racemic mixture, diastereomers, and enantiomers. The following compounds represented by formula (1-1) to (1-4) may be mentioned for the diastereomers, and enantiomers. wherein the definitions and examples of R1, R2, R3, R4, m, and n are as mentioned above.

[0031] <Method of preparing the compound (I)> The compound (I) may be prepared as follows: converting an -NHPMP moiety of a compound represented by a formula (II) to an amino group; and introducing the amino group by reductive amination of a carbonyl group of the compound represented by the formula (II), followed by converting the introduced amino group to a tertiary amino group to form an -NR1R2moiety, wherein the definition and examples of R1, and R2are as mentioned above.

[0032] wherein PMP is a p-methoxyphenyl group, and the definition and examples of R3, R4, m, and n are as mentioned above.

[0033] The compound (II) may be prepared by the method described in the following literature: Y. Garg, F. Tanaka, Org. Lett. 2020, 22, 4542.

[0034] The conversion of the -NHPMP moiety of the compound (II) to the amino group may be performed by using a deprotection agent such as an ammonium cerium nitrate (CAN). For example, the reaction may be performed by using CAN in an appropriate solvent (e.g., a mixture of CH3CN and H2O) at low temperature (e.g., -10 °C to 10 °C). A deprotection agent other than CAN may be used for the conversion. The converted amino group may be protected with Boc group.

[0035] The introduction of the amino group by reductive amination of a carbonyl group of the compound (II) may be performed by using a reducing agent such as Na(OAc)3BH, and NaBH3CN. For example, the compound (II) may be reacted with p-anisidine by using Na(OAc)3BH, and CH3COOH in an appropriate solvent (e.g., 1,2-dichloroethane) at low temperature (e.g., -10 °C to 10 °C). The introduced PMP group may be deprotected by using a deprotection agent mentioned above. For example, the deprotection may be performed by using CAN in the mixture of CH3CN and H2O at 0 °C.

[0036] The conversion of the introduced amino group to a tertiary amino group to form an -NR1R2moiety may be performed using an appropriate reagent depending on R1and R2. The reagent may be a halide (e.g., bromide) containing moiety corresponding to R1and R2. For example, when R1and R2together form a ring, the reagent may be 1,5-dibromopentane, 1,4-dibromobutane, 1,6-dibromohexane, or bis(2-bromoethyl)ether.

[0037] The reaction may be performed in the presence of a base. Examples of the base include K2CO3. The base may be used alone or in a combination of two or more bases. The reaction may be performed in an appropriate solvent (e.g., CH3CN) at 25 °C to 60 °C. The solvent may be used alone or in a combination of two or more solvents.

[0038] The Boc group may be deprotected by trifluoroacetic acid. The obtained reaction product may be subjected to purification,

[0039] For example, a salt of compound (1a) can be prepared by the following method using the compound (2). The compound (2) can be generated by the (S)- β -proline-catalyzed anti-selective Mannich reaction of cyclohexanone with an aryl imine derivative in the presence of K2CO3(Scheme 1). The compound (1a) can be prepared via the route of the compounds from (3) to (6) as illustrated in Scheme 1. Depending on workup conditions after the deprotection of Boc group, the compound (1a) is obtained in the CF3COOH salt form in Scheme 1.

[0040] Scheme 1

[0041] The compound (1a) in the free form can be prepared by changing the workup conditions after the deprotection of Boc group, for example, as illustrated in Scheme 2.

[0042] Scheme 2:

[0043] Other compounds included in the compound (I) and their salts can also be prepared by methods similar to those shown in Schemes 1 and 2, using appropriate starting substances, and reaction conditions.

[0044] <Catalyst> The compound (I) or a salt thereof can be used as a catalyst in various reactions. The present disclosure is also related to a catalyst comprising a compound (I) or the salt. The compound (I) or a salt thereof may be used as a catalyst in a reaction for preparing a Mannich product. In particular, the compound (I) or a salt thereof is useful as a catalyst in a Mannich reaction including a Mannich-aza-Michael reaction. These reactions are advantageous for synthesizing the Mannich product.

[0045] A catalyst comprising the compound (I) or a salt thereof may be used in combination with an acid. Examples of the acid include trifluoroacetic acid. The acid may be used alone or in a combination of two or more acids. The catalyst may be used in combination with dibenzyl phosphate. It is preferred that the catalyst used in combination with trifluoroacetic acid and dibenzyl phosphate.

[0046] An example of the Mannich reaction in which the compound (I) or a salt thereof can be used as a catalyst is as follows: reacting a compound represented by a formula (VIII) with a compound represented by a formula (VII)

[0047] wherein Rcis a hydrogen atom or a monovalent hydrocarbon group which may be substituted with a -P(=O)(ORd)(ORe), a -C(=O)Rd, a -S(=O)2Rd, a -C(=O)ORd, or a -C(=O)NRfRg, wherein Rdis an alkyl, Reis an alkyl, Rfis a hydrogen atom or an alkyl, and Rgis a hydrogen atom or an alkyl. Rcis preferably, an alkyl, an alkenyl, an aryl, a -CH2-P(=O)(ORd)(ORe), a -CH2-C(=O)Rd, a -CH2-S(=O)2Rd, a -CH2-C(=O)ORd, or a -CH2-C(=O)NRfRg, wherein Rd, Re, Rf, and Rgare as defined in the above.

[0048] wherein Rais independently selected from the group consisting of an alkyl, a halogen atom, an alkoxy and a nitro, or two adjacent Ras may form a ring in combination with the carbon atoms they are attached to; s is an integer of 0 to 4; and Rbis a hydrogen atom or an alkoxycarbonyl.

[0049] A Mannich product represented by a formula (IX) may be mentioned as a reaction product. wherein Ra, Rb, Rc, and s are as defined above.

[0050] In the reaction, an amount of the compound (VII) may be 1.5 to 5.0 mol, preferably 2.0 to 4.0 mol, relative to 1.0 mol of the compound (VIII).

[0051] The compound (I) may be used in an amount of 0.1 to 0.8 mol, preferably 0.15 to 0.50 mol, relative to 1.0 mol of the compound (VII). The compound (I) is preferably used with an acid(s) such as trifluoroacetic acid and / or dibenzyl phosphate in a catalytic system. The acid(s) may be used in an amount of 0.1 to 0.8 mol, preferably 0.15 to 0.50 mol, relative to 1.0 mol of the compound (VII). The dibenzyl phosphate may be used in an amount of 0.1 to 0.8 mol, preferably 0.15 to 0.50 mol, relative to 1.0 mol of the compound (VII).

[0052] The reaction may be performed in a solvent. Examples of the solvent include an aromatic hydrocarbon solvent such as benzene, toluene, xylene). The reaction may be performed in the temperature range of -10 to 60°C, preferably performed at room temperature (25°C).

[0053] In particular, the enantiomers of the compound (1-1) or the compound (1-2) mentioned above accelerate the enantioselective, γ -position-selective Mannich reactions of β-ketophosphonates. They also accelerate the enantioselective γ-position-selective Mannich reactions of β-ketocarbonyl compounds.

[0054] As illustrated in Scheme 3, the compound (1a) which is included in the compound (1-1) has a primary amine group and a tertiary amine group with a 1,3-relationship (Scheme 1). The compound (1a) accelerates enantioselective, γ-position-selective Mannich reactions of Mannich products.

[0055] Scheme 3:

[0056] With respect to the compounds (1-1) and (1-2), the primary amine group may lead to the formation of enamine intermediates during the catalysis. It is presumed that the attachment of the tertiary amine group and the amino(aryl)methyl group moiety on a cyclohexane ring to position the amine groups in a 1,3-relationship would result in catalytic functions.

[0057] In case where the above Mannich reaction is performed in the presence of the compound (1-1), the compound represented by the formula (9-1) may be obtained, and in the presence of the compound (1-2), the compound represented by the formula (9-2) may be obtained, wherein Ra, Rb, Rc, and s are as defined above.

[0058] In order to obtain the compound (9-1) or the compound (9-2) with high yield with high enantioselectivities, it is preferred that the reaction is carried out by using acid addition salt of the compound (1) as a catalyst together with dibenzyl phosphate. It is also preferred that the reaction is carried out by the compound (1) in a free form as a catalyst together with an acid (e.g. a trifluoroacetic acid) and dibenzyl phosphate.

[0059] In the case where a compound represented by a formula (VII’) is used as the compound of the formula (VII), a Mannich-aza-Michael reaction takes place and a cyclized Mannich product represented by a formula (9-3) may be obtained.

[0060] wherein Rhis a hydrogen atom, a -P(=O)(ORd)(ORe), a -C(=O)Rd, a -S(=O)2Rd, a -C(=O)ORd, a -C(=O)NRfRg, or a monovalent hydrocarbon group which may be substituted with a -P(=O)(ORd)(ORe), a -C(=O)Rd, a -S(=O)2Rd, a -C(=O)ORd, or a -C(=O)NRfRg, wherein Rd, Re, Rf, and Rgare as defined in the above; wherein Ra, Rb, and s are as defined in the above; and Rhis as defined in the above.

[0061] Rhis preferably a hydrogen atom, analkyl, anaryl, a -CH2-P(=O)(ORd)(ORe), a -CH2-C(=O)Rd, a -CH2-S(=O)2Rd, a -CH2-C(=O)ORd, or a -CH2-C(=O)NRfRg(wherein Rd, Re, Rf, and Rgare as defined in the above), more preferably, a hydrogen atom or a straight-chain alkyl. The straight-chain alkyl preferably has 1 to 12 carbon atoms, more preferably 1 to 8 carbon atoms, further more preferably 1 to 3 carbon atoms.

[0062] In this reaction, Rbis preferably a hydrogen.

[0063] In the reaction, an amount of the compound (VII’) may be 1.5 to 5.0 mol, preferably 2.0 to 4.0 mol, relative to 1.0 mol of the compound (VIII). The compound (I) may be used in an amount of 0.1 to 0.8 mol, preferably 0.15 to 0.50 mol, relative to 1.0 mol of the compound (VII’). The compound (I) is preferably used with an acid(s) such as trifluoroacetic acid and / or dibenzyl phosphate in a catalytic system. The acid(s) may be used in an amount of 0.1 to 0.8 mol, preferably 0.15 to 0.50 mol, relative to 1.0 mol of the compound (VII’). The dibenzyl phosphate may be used in an amount of 0.1 to 0.8 mol, preferably 0.15 to 0.50 mol, relative to 1.0 mol of the compound (VII’). The reaction may be performed in a solvent. Examples of the solvent include an aromatic hydrocarbon solvent such as benzene, toluene, xylene). The reaction may be performed in the temperature range of -10 to 60°C, preferably at room temperature (25°C).

[0064] <Application> Applications of the compound (I) or a salt thereof are not limited to a catalyst, but include pharmaceuticals, raw materials for polymeric materials.Examples

[0065] The following provides more specific descriptions of the present disclosure based on certain examples.

[0066] Example 1 (Synthesis of catalysts)

[0067] 1. Synthesis of Compound 1a

[0068] Compound 1a was synthesized as illustrated in Scheme 4.

[0069] Scheme 4

[0070] (Synthesis of Compound 2) Compound 2 was synthesized by the procedures disclosed in Y. Garg, F. Tanaka, Org. Lett. 2020, 22, 4542. K2CO3(691 mg, 5.00 mmol) was added to a solution of (S)-3-pyrrolidinecarboxylic acid (575 mg, 5.00 mmol) in N-methylpyrrolidone (NMP) (15 mL), and the mixture was stirred at room temperature (25 °C, rt) for 1 h. The mixture was cooled to 0oC, and CF3SO2NH2(745 mg, 5.00 mmol), CHCl3(35 mL), and cyclohexanone (51.8 mL, 500 mmol) were added to the mixture. The mixture was stirred at the same temperature for 5 min, and the N-p-methoxyphenyl (PMP)-protected imine (14.5 g, 50.0 mmol), which was prepared from 4-bromobenzaldehyde and p-anisidine, was added. The mixture was stirred at 0 °C for 192 h. The mixture was diluted with EtOAc (100 mL) and then H2O (100 mL) was added to the mixture, and the mixture was extracted with EtOAc. Organic layers were combined, washed with brine, dried over anhydrous Na2SO4, filtered, concentrated in vacuo, and purified by flash column chromatography (hexane / EtOAc = 85:15) to give Compound 2 (17.4 g, 90%, anti / syn >96:4, er 95:5) as a colorless oil.

[0071] Compound 2 The characterization data of Compound 2 was consistent with the data described in the literature Organic Letters 2020, 22, 4542.

[0072] (Synthesis of Compound 3) A solution of ammonium cerium nitrate (CAN) (120 g, 220 mmol) in H2O (300 mL) was added to a solution of Compound 2 (anti / syn >96:4, er 95:5, 19.40 g, 50.0 mmol) in CH3CN (400 mL) at 0 °C, and the mixture was stirred at the same temperature for 2 h. The mixture was diluted with water (500 mL) and extracted with EtOAc (100 mL x 3). Organic layers were combined, dried over Na2SO4, filtered, concentrated, and purified by flash column chromatography (CH2Cl2 / MeOH = 90:10) to give Compound 3 (8.70 g, 63%, dr >96:4) as a colorless oil.

[0073] Compound 3 1H NMR (500 MHz, CD3OD): δ 7.64 (d, J = 8.5 Hz, 2H), 7.35 (d, J = 8.5 Hz, 2H), 4.44 (d, J = 10.0 Hz, 1H), 3.11-3.04 (m, 1H), 2.58-2.43 (m, 2H), 2.18-2.07 (m, 1H), 1.84-1.75 (m, 1H), 1.75-1.54 (m, 3H), 1.28 (qd, J = 13.0 Hz, 4.0 Hz, 1H).13C NMR (125 MHz, CD3OD): δ 213.1, 135.7, 133.6, 130.9, 124.5, 56.1, 53.6, 43.0, 32.7, 28.9, 25.5. HRMS (ESI): m / z calcd for C13H17NOBr [M+H]+282.0488, found 282.0497.

[0074] (Synthesis of Compound 4) NaHCO3(7.77 g, 92.5 mmol) and di-tert-butyl decarbonate (8.5 mL, 37 mmol) were added to a solution of Compound 3 (dr >96:4, 8.70 g, 30.9 mmol) in THF / H2O (1:1 (v / v), 100 mL) at 0 °C, and the mixture was stirred at room temperature (25 °C) for 12 h. The mixture was concentrated to remove the organic solvent and extracted with EtOAc (50 mL x 3). Organic layers were combined, dried over Na2SO4, concentrated, and crystallized from EtOH to give Compound 4 (6.84 g, 58%, anti / syn >96:4, anti-isomer er 99.8:0.2) as a colorless solid.

[0075] Compound 4 1H NMR (500 MHz, CDCl3): δ 7.41 (d, J = 8.5 Hz, 2H), 7.18 (d, J = 8.5 Hz, 2H), 5.79 (brs, 1H), 4.82-4.72 (m, 1H), 2.87-2.80 (m, 1H), 2.38-2.32 (m, 1H), 2.32-2.23 (m, 1H), 2.16-2.07 (m, 1H), 2.07-1.97 (m, 1H), 1.94-1.85 (m, 1H), 1.78-1.64 (m, 3H), 1.40 (s, 9H).13C NMR (125 MHz, CDCl3): δ 212.5, 155.6, 140.8, 131.3, 128.3, 120.7, 79.6, 55.9, 54.8, 42.6, 32.5, 28.3, 28.0, 24.4. HRMS (ESI): m / z calcd for C18H25NO3Br [M+H]+382.1012, found 382.1017. HPLC (Daicel Chiralpak IC-3, hexane / i-PrOH = 90:10, flow rate = 0.5 mL / min, λ = 220 nm): tR17.7 min (minor enantiomer), 42.5 min (major enantiomer). For (±)-4 (anti / syn = 5:1), HPLC (Daicel Chiralpak IC-3, hexane / i-PrOH = 90:10, flow rate = 0.5 mL / min, λ = 220 nm): tR17.8 min (anti-isomer), 18.4 min (syn-isomer), 24.2 min (syn-isomer), 42.8 (anti-isomer).

[0076] Compound ent-4 Colorless solid, dr >96:4, er 0.1:>99.9. HPLC (Daicel Chiralpak IC-3, hexane / i-PrOH = 90:10, flow rate = 0.5 mL / min, λ = 220 nm): tR16.5 min (major enantiomer). For (±)-4 (anti / syn = 9:1), HPLC (Daicel Chiralpak IC-3, hexane / i-PrOH = 90:10, flow rate = 0.5 mL / min, λ = 220 nm): tR16.5 min (anti-isomer), 17.8 min (syn-isomer), 20.8 min (syn-isomer), 32.8 (anti-isomer).

[0077] (Synthesis of Compound 5) p-Anisidine (2.62 g, 21.3 mmol) was added to a solution of Compound 4 (dr >96:4, er 99.8:0.2, 6.80 g, 17.8 mmol) in 1,2-dichloroethane (190 mL) at 0 °C, and the mixture was stirred for 5 min. To the mixture, Na(OAc)3BH (11.3 g, 53.4 mmol) and CH3COOH (3.05 mL, 53.4 mmol) were added at the same temperature, and the mixture was stirred for 24 h at the same temperature. Further Na(OAc)3BH (11.3 g, 53.4 mmol) and CH3COOH (3.05 mL, 53.4 mmol) were added, and the mixture was stirred at the same temperature for another 24 h. The mixture was quenched by addition of saturated aqueous NaHCO3solution and extracted with CH2Cl2(100 mL x 3). The organic layers were combined, dried over Na2SO4, filtered, concentrated, and purified by flash column chromatography (hexane / EtOAc = 90:10) to give reductive amination product (8.70 g, 99%, dr 3.4:1) as a colorless oil. A solution of ammonium cerium nitrate (CAN) (35.5 g, 64.7 mmol) in H2O (170 mL) was added to a solution of this compound (dr 3.4:1, 7.20 g, 14.7 mmol) in CH3CN (230 mL) at 0 °C, and the mixture was stirred at the same temperature for 2 h. The mixture was diluted with water (300 mL) and extracted with EtOAc (100 mL x 3). Organic layers were combined, dried over Na2SO4, filtered, concentrated, and purified by flash column chromatography (CH2Cl2 / MeOH = 97:3) to give Compound 5 (4.51 g, 80%, single diastereomer, er 99.5:0.5) as a colorless oil and a mixture of 5 and its diastereomer (600 mg, 14%, dr 3:1, the major was Compound 5 and the minor was a diastereomer of Compound 5).

[0078] Compound 5 [α]25D+58.0 (c 0.4, MeOH, single diastereomer, er 99.5:0.5).1H NMR (500 MHz, CD3OD): δ 7.52 (d, J = 8.5 Hz, 2H), 7.23 (d, J = 8.5 Hz, 2H), 4.29 (d, J = 11.5 Hz, 1H), 3.74-3.70 (m, 1H), 2.09-1.98 (m, 2H), 1.81-1.60 (m, 3H), 1.49-1.39 (m, 1H), 1.44 (s, 9H), 1.27-1.12 (m, 2H), 1.08-1.01 (m, 1H).13C NMR (125 MHz, CD3OD): δ 159.3, 140.5, 133.0, 130.4, 122.7, 81.6, 57.5, 49.7, 45.4, 30.1, 28.6, 25.7, 24.2, 19.9. HRMS (ESI): m / z calcd for C18H28N2O2Br [M+H]+383.1329, found 383.1338. HPLC (Daicel Chiralpak IC-3, hexane / i-PrOH / 2-aminoethanol 90:10:0.1, flow rate = 1.0 mL / min, λ = 220 nm): tR7.6 min (minor enantiomer), 11.0 min (major enantiomer).

[0079] Compound ent-5 [α]25D-49.2 (c 0.4, MeOH, er 0.1:>99.9). HPLC (Daicel Chiralpak IC-3, hexane / i-PrOH / 2-aminoethanol 90:10:0.1, flow rate = 1.0 mL / min, λ = 220 nm): tR7.2 min (major enantiomer).

[0080] Compound 5 and the diastereomer (dr 3:1)1H NMR (400 MHz, CD3OD): δ 7.58-7.42 (m, 2H), 7.38-7.29 (m, 2H x 1 / 4), 7.23 (d, J = 8.3 Hz, 2H x 3 / 4), 4.44 (d, J = 10 Hz, 1H x 1 / 4), 4.29 (d, J = 11.8 Hz, 1H x 3 / 4), 3.81-3.61 (m, 1H x 3 / 4), 3.19-3.00 (m, 1H x 1 / 4), 2.20-1.92 (m, 2H), 1.92-0.84 (m, 17H).

[0081] (Synthesis of Compound 6) K2CO3(6.29 g, 45.5 mmol) and 1,5-dibromopentane (6.15 mL, 45.5 mmol) were added to a solution of Compound 5 (single diastereomer, er 99.5:0.5, 5.82 g, 15.2 mmol) in CH3CN (100 mL) at room temperature (25 °C), and the mixture was refluxed at 60 °C (oil bath) for 18 h. The mixture was cooled to room temperature (25 °C), diluted with water, and extracted with EtOAc (50 mL x 3). Organic layers were combined, dried over Na2SO4, filtered, and concentrated. The residue was dissolved in MeOH(20 mL), and the generated solid was collected by filtration to give Compound 6 (4.41 g, 64%, single diastereomer) as a colorless solid.

[0082] Compound 6 1H NMR (500 MHz, CDCl3): δ 9.79 (s, 1H), 7.38 (d, J = 8.5 Hz, 2H), 7.18 (d, J = 8.5 Hz, 2H), 4.62 (d, J = 6.5 Hz, 1H), 3.03-2.70 (brm, 2H), 2.35-2.28 (m, 1H), 2.05-1.95 (m, 1H), 2.19-1.90 (m, 1H), 1.90-1.55 (m, 8H), 1.55-1.45 (m, 1H), 1.45-1.10 (m, 15H).13C NMR (125 MHz, CDCl3): δ 156.6, 143.7, 131.0, 128.6, 120.0, 78.0, 67.0, 55.3, 53.5, 49.6, 40.0, 28.3, 27.1, 26.3, 25.9, 24.3, 23.6, 20.6. HRMS (ESI): m / z calcd for C23H36N2O2Br [M+H]+451.1955, found 451.1966. Compound 6 was crystallized from MeOH for X-ray crystal structural analysis. Colorless crystals, mp 145-150 °C.

[0083] (Synthesis of Compound 1a・CF3COOH) CF3COOH (15 mL) was added to a solution of Compound 6 (3.50 g, 7.76 mmol) in CH2Cl2(3 mL), at room temperature (25 °C), and the mixture was stirred for 5 h at the same temperature. The mixture was concentrated, and a saturated aqueous NaHCO3solution was added (resulting pH ~7). The mixture was extracted with EtOAc (50 mL x 3). Organic layers were combined, dried over Na2SO4, filtered, concentrated, and purified by flash column chromatography (CH2Cl2 / MeOH = 95:5) to give Compound 1a・CF3COOH (1:1) (2.52 g, 70%, single diastereomer, er >99.9:0.1) as a colorless solid. The ratio between Compound 1a and CF3COOH was determined to be 1:1 by13C NMR analysis using inverse gated1H decoupling mode (pulse program: zgig30, D1: 30 sec).

[0084] [α]25D-11.5 (c 1.0, MeOH, er >99.9:0.1).1H NMR (500 MHz, CD3OD): δ 7.57 (d, J = 8.5 Hz, 2H), 7.38 (d, J = 8.5 Hz, 2H), 4.39 (d, J = 11.5 Hz, 1H), 3.81-3.69 (brm, 1H), 3.50-3.37 (brm, 1H), 3.12 (dt, J = 12.5 Hz, 3.5 Hz, 1H), 2.69-2.49 (m, 3H), 2.13-2.07 (m, 1H), 2.01-1.19 (m, 13H).13C NMR (125 MHz, CD3OD): δ 162.9 (q, JC,F= 34 Hz), 141.7, 133.2, 130.2, 122.9, 118.2 (q, JC,F= 290 Hz), 69.2, 55.0, 53.6, 37.4, 28.6, 26.4, 26.1, 25.7, 24.1, 23.7, 20.1. HRMS (ESI): m / z calcd for C18H28N2Br [M+H]+351.1430, found 351.1438. HPLC (Daicel Chiralpak IC-3, hexane / i-PrOH / 2-aminoethanol 90:10:0.1, flow rate = 1.0 mL / min, λ = 220 nm): tR5.9 min (major enantiomer). For (±)-1a・CF3COOH, HPLC (the same conditions): tR5.8 min and 7.1 min. Compound 1a・CF3COOH was crystallized from EtOAc for X-ray crystal structural analysis. Colorless crystals, mp 190-195 °C. The X-ray crystal structure of Compound 1a・CF3COOH is illustrated in FIG. 1.

[0085] Compound ent-1a・CF3COOH [α]25D+4.4 (c 1.0, MeOH, er 0.1:>99.9). HPLC (Daicel Chiralpak IC-3, hexane / i-PrOH / 2-aminoethanol 90:10:0.1, flow rate = 1.0 mL / min, λ = 220 nm): tR8.1 min (major enantiomer). For (±)-1a・CF3COOH, HPLC (the same conditions): tR6.1 min and 7.8 min.

[0086] (Formation of Compound 1a (free form)) A mixture of 1a・CF3COOH (single diastereomer, 50 mg, 0.1 mmol) and a saturated aqueous NaHCO3solution (15 mL) (resulting pH ~8) was stirred at room temperature (25 °C) for 10 min. The mixture was extracted with CH2Cl2(20 mL x 3). Organic layers were combined, washed with saturated aqueous NaCl solution (15 mL), dried over Na2SO4, filtered, and concentrated to give Compound 1a (free form) (35 mg, 90%, single diastereomer, er >99.9:0.1) as a colorless solid.

[0087] Compound 1a (free form) [α]25D+2.95 (c 0.5, MeOH, er >99.9:0.1).1H NMR (500 MHz, CD3OD): δ 7.48 (d, J = 8.5 Hz, 2H), 7.30 (d, J = 8.5 Hz, 2H), 4.20 (d, J = 10.4 Hz, 1H), 3.05-2.42 (brm, 3H), 2.59 (dt, J = 10.8 Hz, 3.8 Hz, 1H), 2.38-2.28 (m, 1H), 1.93-1.85 (m, 1H), 1.85-1.78 (m, 1H), 1.78-1.71 (m, 1H), 1.71-1.55 (m, 4H), 1.55-1.41 (m, 2H), 1.41-1.05 (m, 6H).13C NMR (125 MHz, CD3OD): δ 144.4, 132.6, 130.7, 121.8, 67.7, 56.4, 53.0, 41.5, 29.4, 27.5, 26.7, 25.3, 25.0, 21.8. HPLC (Daicel Chiralpak IC-3, hexane / i-PrOH / 2-aminoethanol 90:10:0.1, flow rate = 1.0 mL / min, λ = 220 nm): tR5.9 min (major enantiomer). For (±)-1a・CF3COOH (1:1), HPLC (the same conditions): tR5.8 min and 7.1 min; the HPLC eluent included 2-aminoethanol and thus the CF3COOH salt form of Compound 1a and free form of Compound 1a afforded the same retention time.

[0088] 2. Synthesis of compound ent-1a Compound ent-1a was synthesized by the same procedures as those used for the synthesis of Compound 1a but using (R)-3-pyrrolidinecarboxylic acid in the formation of the enantiomer of Compound 2 instead of (S)-3-pyrrolidinecarboxylic acid in the formation of Compound 2.

[0089] 3. Synthesis of Compound 1b

[0090] Compound 1b was synthesized as illustrated in Scheme 5.

[0091] Scheme 5

[0092] (Synthesis of compound S1) Compound 5 was synthesized by the same procedures as those used for the synthesis of Compound 1a. K2CO3(853 mg, 6.17 mmol) and 1,4-dibromobutane (728 μL, 6.17 mmol) were added to a solution of Compound 5 (single diastereomer, er 99.5:0.5, 800 mg, 2.05 mmol) in CH3CN (15 mL) at room temperature (25 °C), and the mixture was refluxed at 60 °C (oil bath) for 24 h. The mixture was cooled to room temperature (25 °C), diluted with water, and extracted with EtOAc (10 mL x 3). Organic layers were combined, dried over Na2SO4, filtered, concentrated, and purified by column chromatography (CH2Cl2 / MeOH = 97:3) to give Compound S1 (708 mg, 78%, single diastereomer) as a colorless oil.

[0093] Compound S1 1H NMR (500 MHz, CDCl3): δ 9.87 (s, 1H), 7.40 (d, J = 8.2 Hz, 2H), 7.22 (d, J = 8.2 Hz, 2H), 4.80-4.50 (brs, 1H), 3.00-2.00 (m, 5H), 2.10-2.00 (m, 1H), 1.90-1.74 (m, 5H), 1.74-1.50 (m, 2H), 1.50-1.00 (m, 14H).13C NMR (125 MHz, CDCl3): δ 157.0, 144.2, 131.1, 128.7, 120.1, 78.0, 68.3, 55.6, 51.6, 40.5, 28.3, 26.9, 25.8, 25.7, 23.2, 20.2. HRMS (ESI): m / z calcd for C22H34N2O2Br [M+H]+437.1798, found 437.1800.

[0094] (Synthesis of Compound 1b・CF3COOH) CF3COOH (1.0 mL) was added to a solution of compound S1 (single diastereomer, 700 mg, 1.6 mmol) in CH2Cl2(500 μL) at room temperature (25 °C), and the mixture was stirred for 1 h at the same temperature. The mixture was concentrated, and a saturated aqueous NaHCO3solution was added (resulting pH ~7). The mixture was extracted with EtOAc (10 mL x 3). Organic layers were combined, dried over Na2SO4, filtered, concentrated, and purified by flash column chromatography (CH2Cl2 / MeOH = 95:5) to give Compound 1b・CF3COOH (1:1) (385 mg, 53%, single diastereomer, er >99.9:0.1) as a colorless solid. The ratio between Compound 1b and CF3COOH was determined to be 1:1 by13C NMR analysis using inverse gated1H decoupling mode (pulse program: zgig30, D1: 30 sec).

[0095] Compound 1b・CF3COOH [α]24D-1.3 (c 1.0, MeOH, er >99.9:0.1).1H NMR (500 MHz, CD3OD): δ 7.57 (d, J = 8.5 Hz, 2H), 7.37 (d, J = 8.5 Hz, 2H), 4.48 (d, J = 12.0 Hz, 1H), 3.50-2.85 (brm, 4H), 3.15 (dt, J = 12.5 Hz, 3.5 Hz, 1H), 2.61-2.55 (m, 1H), 2.10-1.90 (m, 7H), 1.48-1.18 (m, 5H).13C NMR (125 MHz, CD3OD): δ 163.0 (q, JC,F= 34 Hz), 141.7, 133.2, 130.2, 123.0, 118.2 (q, JC,F= 291 Hz), 69.4, 55.3, 52.4, 38.8, 28.3, 26.2, 25.6, 23.7, 19.9. HRMS (ESI): m / z calcd for C17H26N2Br [M+H]+337.1274, found 337.1295. HPLC (Daicel Chiralpak IC-3, hexane / i-PrOH / 2-aminoethanol 90:10:0.1, flow rate = 1.0 mL / min, λ = 220 nm): tR5.8 min (major enantiomer). For (±)-1b・CF3COOH (1:1), HPLC (the same conditions): tR5.8 min and 6.8 min.

[0096] (Formation of Compound 1b (free form)) A mixture of Compound 1b・CF3COOH (single diastereomer, 20 mg, 0.044 mmol) and a saturated aqueous NaHCO3solution (10 mL) (resulting pH ~8) was stirred at room temperature (25 °C) for 10 min. The mixture was extracted with CH2Cl2(20 mL x 3). Organic layers were combined, washed with saturated aqueous NaCl solution (10 mL), dried over Na2SO4, filtered, and concentrated to give Compound 1b (free form) (12 mg, 80%, single diastereomer) as a pale yellow solid.

[0097] Compound 1b (free form) [α]25D+1092.8 (c 1.0, MeOH, er (based on compound 1b・CF3COOH) >99.9:0.1).1H NMR (500 MHz, CD3OD): δ 7.49 (d, J = 8.5 Hz, 2H), 7.32 (d, J = 8.5 Hz, 2H), 4.35 (d, J = 11.0 Hz, 1H), 3.06-2.76 (m, 2H), 2.74-2.57 (m, 2H), 2.53 (dt, J = 12.0 Hz, 3.5 Hz, 1H), 2.39-2.31 (m, 1H), 1.99-1.72 (m, 7H), 1.49-1.26 (m, 2H), 1.26-1.07 (m, 3H).13C NMR (125 MHz, CD3OD): δ 144.5, 132.7, 130.6, 121.9, 70.1, 56.1, 53.4, 42.1, 29.3, 27.1, 26.7, 24.0, 21.0.

[0098] 4. Synthesis of Compound 1c

[0099] Compound 1c was synthesized as illustrated in Scheme 6.

[0100] Scheme 6

[0101] (Synthesis of Compound S2) Compound 5 was synthesized by the same procedures as those used for the synthesis of compound 1a. K2CO3(212 mg, 1.54 mmol) and 1,6-dibromohexane (220 μL, 1.54 mmol) were added to a solution of Compound 5 (single diastereomer, er 99.5:0.5, 200 mg, 0.514 mmol) in CH3CN (5 mL) at room temperature (25 °C), and the mixture was refluxed at 60 °C (oil bath) for 24 h. The mixture was cooled to room temperature (25 °C), diluted with water, and extracted with EtOAc (10 mL x 3). Organic layers were combined, dried over Na2SO4, filtered, concentrated, and purified by column chromatography (CH2Cl2 / MeOH = 97:3) to give Compound S2 (152 mg, 63%, single diastereomer) as a colorless oil.

[0102] Compound S2 1H NMR (500 MHz, CD3OD): δ 7.46 (d, J = 8.5 Hz, 2H), 7.18 (d, J = 8.5 Hz, 2H), 4.50 (d, J = 7.5 Hz, 1H), 3.47 (t, J = 6.5 Hz, 2H), 2.78-2.68 (m, 2H), 2.36-2.28 (m, 1H), 1.95-1.15 (m, 26H).13C NMR (125 MHz, CD3OD): δ 157.8, 143.6, 132.3, 129.8, 121.4, 80.0, 58.7, 54.4, 47.4, 34.4, 33.9, 30.9, 29.5, 29.1, 28.8, 27.7, 27.0, 26.2, 20.6. HRMS (ESI): m / z calcd for C24H38N2O2Br [M+H]+465.2111, found 465.2105.

[0103] (Synthesis of Compound 1c・CF3COOH) CF3COOH (2.4 mL) was added to a solution of Compound S2 (single diastereomer, 150 mg, 0.32 mmol) in CH2Cl2(1.2 mL) at room temperature (25 °C), and the mixture was stirred for 1 h at the same temperature. The mixture was concentrated, and a saturated aqueous NaHCO3solution was added (resulting pH ~7). The mixture was extracted with EtOAc. Organic layers were combined, dried over Na2SO4, filtered, concentrated, and purified by flash column chromatography (CH2Cl2 / MeOH = 95:5) to give Compound 1c・CF3COOH (65 mg, 43%, single diastereomer) as a colorless solid.

[0104] Compound 1c・CF3COOH 1H NMR (500 MHz, CD3OD): δ 7.55 (d, J = 8.5 Hz, 2H), 7.33 (d, J = 8.5 Hz, 2H), 4.33 (d, J = 10.0 Hz, 1H), 3.47 (t, J = 6.5 Hz, 2H), 3.25 (dt, J = 11.0 Hz, 3.5 Hz, 1H), 3.12 (dt, J = 11.0 Hz, 8.0 Hz, 1H), 2.97-2.90 (m, 1H), 2.40-2.34 (m, 1H), 2.04-1.82 (m, 5H), 1.74-1.64 (m, 2H), 1.59-1.23 (m, 9H).13C NMR (125 MHz, CD3OD): δ 162.9 (q, JC,F= 33.7 Hz), 143.2, 133.1, 129.8, 122.5, 118.2 (q, JC,F= 291 Hz), 61.5, 55.9, 46.9, 39.2, 34.2, 33.6, 28.8, 28.1, 27.9, 26.9, 26.8, 24.9, 21.2. HRMS (ESI): m / z calcd for C19H30N2Br [M+H]+365.1587, found 365.1581.

[0105] (Formation of Compound 1c (free form)) A mixture of 1c・CF3COOH (single diastereomer, 15 mg, 0.031 mmol) and a saturated aqueous NaHCO3solution (5 mL) (resulting pH ~8) was stirred at room temperature (25 °C) for 10 min. The mixture was extracted with CH2Cl2(10 mL x 3). Organic layers were combined, washed with saturated aqueous NaCl solution (5 mL), dried over Na2SO4, filtered, and concentrated to give Compound 1c (free form) (10 mg, 88%, single diastereomer) as a colorless solid.

[0106] Compound 1c (free form) [α]25D+2.52 (c 0.5, MeOH, er (based on compound 5) 99.5:0.5).1H NMR (500 MHz, CD3OD): δ 7.49 (d, J = 8.4 Hz, 2H), 7.26 (d, J = 8.5 Hz, 2H), 3.97 (d, J = 9.7 Hz, 1H), 3.50-3.43 (m, 2H), 3.09-3.03 (m, 1H), 2.86-2.77 (m, 1H), 2.68-2.58 (m, 1H), 2.06-1.94 (m, 1H), 1.93-1.77 (m, 3H), 1.69-1.05 (m, 13H).13C NMR (125 MHz, CD3OD): δ 144.9, 132.6, 130.2, 121.8, 57.8, 56.5, 47.7, 45.9, 34.3, 33.8, 30.3, 29.0, 28.4, 27.5, 26.7, 25.0, 22.3.

[0107] 5. Synthesis of Compound 1d

[0108] Compound 1d was synthesized as illustrated in Scheme 7.

[0109] Scheme 7

[0110] (Synthesis of Compound S3) Compound 5 was synthesized by the same procedures as those used for the synthesis of compound 1a. K2CO3(960 mg, 6.94 mmol) and bis(2-bromoethyl)ether (865 μL, 6.94 mmol) were added to a solution of compound 5 (single diastereomer, er 99.5:0.5, 900 mg, 2.31 mmol) in CH3CN (20 mL) at room temperature (25 °C), and the mixture was refluxed at 60 °C (oil bath) for 24 h. The mixture was cooled to room temperature (25 °C), diluted with water, and extracted with EtOAc (10 mL x 3). Organic layers were combined, dried over Na2SO4, filtered, concentrated, and purified by column chromatography (CH2Cl2 / MeOH = 97:3) to give Compound S3 (810 mg, 76%, single diastereomer) as a colorless solid.

[0111] Compound S3 1H NMR (500 MHz, CD3OD): δ 7.45 (d, J = 8.5 Hz, 2H), 7.23 (d, J = 8.5 Hz, 2H), 4.65 (d, J = 10.0 Hz, 1H), 3.85-3.72 (m, 4H), 2.80-2.43 (m, 5H), 2.15-2.07 (m, 1H), 1.93-1.78 (m, 2H), 1.73-1.61 (m, 1H) 1.61-1.50 (m, 1H), 1.50-1.19 (m, 13H).13C NMR (125 MHz, CD3OD): δ 158.1, 144.8, 132.3, 130.2, 121.3, 79.8, 68.4, 67.7, 56.6, 52.4, 41.3, 28.7, 28.0, 26.6, 24.5, 22.1. HRMS (ESI): m / z calcd for C22H34N2O3Br [M+H]+453.1747, found 453.1748.

[0112] (Synthesis of Compound 1d・CF3COOH) CF3COOH (2.0 mL) was added to a solution of Compound S3 (single diastereomer, 400 mg, 0.88 mmol) in CH2Cl2(2.0 mL) at room temperature (25 °C), and the mixture was stirred for 1 h at the same temperature. The mixture was concentrated, and a saturated aqueous NaHCO3solution was added (resulting pH ~7). The mixture was extracted with EtOAc (10 mL x 3). Organic layers were combined, dried over Na2SO4, filtered, concentrated, and purified by flash column chromatography (CH2Cl2 / MeOH = 95:5) to give 1d・CF3COOH (1:1) (240 mg, 58%, single diastereomer) as a colorless solid.

[0113] Compound 1d・CF3COOH 1H NMR (500 MHz, CDCl3): δ 9.36 (brs, 2H), 7.46 (d, J = 8.0 Hz, 2H), 7.31 (d, J = 8.0 Hz, 2H), 4.41 (d, J = 11.5 Hz, 1H), 3.92-3.80 (m, 2H), 3.45-3.37 (m, 1H), 3.37-3.23 (m, 2H), 2.88-2.81 (m, 1H), 2.75-2.68 (m, 1H), 2.55 (dt, J = 12.5 Hz, 3.1 Hz, 1H), 2.29-2.21 (m, 1H), 2.21-2.12 (m, 1H), 1.98-1.86 (m, 2H), 1.53 (qd, J = 12.5 Hz, 3.1 Hz, 1H), 1.33-1.00 (m, 5H).13C NMR (125 MHz, CDCl3): δ 161.2 (q, JC,F= 35 Hz), 134.4, 132.2, 129.6, 123.3, 116.4 (q, JC,F= 291 Hz), 67.0, 66.8, 66.4, 54.4, 51.9, 49.2, 34.9, 26.9, 25.2, 23.1, 19.1. HRMS (ESI): m / z calcd for C17H26N2OBr [M+H]+353.1223, found 353.1232.

[0114] (Formation of Compound 1d (free form)) A mixture of 1d・CF3COOH (1:1) (single diastereomer, 40 mg, 0.086 mmol) and a saturated aqueous NaHCO3solution (resulting pH ~8) was stirred at room temperature (25 °C) for 10 min. The mixture was extracted with CH2Cl2. Organic layers were combined, washed with saturated aqueous NaCl solution, dried over Na2SO4, filtered, and concentrated to give Compound 1d (free form) (25 mg, 84%, single diastereomer) as a colorless solid.

[0115] Compound 1d (free form) [α]25D+423.4 (c 1.0, CH2Cl2, er (based compound 5) 99.5:0.5).1H NMR (500 MHz, CDCl3): δ 7.43 (d, J = 8.5 Hz, 2H), 7.24 (d, J = 8.5 Hz, 2H), 4.27 (d, J = 10.0 Hz, 1H), 3.82-3.63 (m, 4H), 3.09-2.33 (m, 6H), 2.41 (dt, J = 11.0 Hz, 3.6 Hz, 1H), 2.31-2.20 (m, 1H), 1.91-1.73 (m, 2H), 1.70-1.55 (m, 1H), 1.42-1.05 (m, 5H).13C NMR (125 MHz, CDCl3): δ 144.3, 131.3, 129.3, 120.5, 67.3, 66.8, 55.3, 51.7, 40.4, 28.4, 25.5, 23.7, 20.9.

[0116] 6. Synthesis of Compound 1e

[0117] Compound 1e was synthesized as illustrated in Scheme 8.

[0118] Scheme 8

[0119] (Synthesis of Compound S4) Compound 5 was synthesized by the same procedures as those used for the synthesis of compound 1a. HCHO (37% (w / w) in H2O, 1.62 mL, 20 mmol), NaCNBH3(377 mg, 6.0 mmol), and AcOH (343 μL, 6.0 mmol) were added to a solution of Compound 5 (single diastereomer, er 99.5:0.5, 778 mg, 2.0 mmol) in CH3CN (8 mL), at room temperature (25 °C), and the mixture was stirred for 21 h. The mixture was diluted with water and extracted with EtOAc (20 mL x 3). Organic layers were combined, dried over Na2SO4, filtered, concentrated, and purified by flash column chromatography (CH2Cl2 / MeOH = 97:3) to give a mixture of Compound S4 and S4' (S4 / S4' = 9:1, 800 mg) as a colorless oil.

[0120] Compounds S4 and S4' (9:1)1H NMR (500 MHz, CD3OD): δ 7.46 (d, J = 8.0 Hz, 2H), 7.23 (d, J = 8.0 Hz, 2H x 9 / 10), 7.19 (d, J = 8.0 Hz, 2H x 1 / 10), 4.61 (d, J = 10.0 Hz, 1H), 2.39 (s, 6H x 9 / 10), 2.23 (s, 6H, 1 / 10), 2.22-2.10 (m, 1H), 1.98-1.80 (m, 2H), 1.78-1.48 (m, 3H), 1.48-0.97 (m, 13H).13C NMR (125 MHz, CD3OD): δ 158.4, 132.5, 132.2, 130.2, 121.3, 80.0, 56.8, 43.7, 41.4, 30.7, 28.8, 28.7, 28.6, 28.0, 26.6, 25.5, 21.7. HRMS (ESI): m / z calcd for C20H32N2O2Br [M+H]+411.1642, found 411.1651 for compound S4.

[0121] (Synthesis of Compound 1e・CF3COOH) CF3COOH (2.0 mL) was added to a solution of Compound S4 and S4' (S4 / S4' = 9:1, 800 mg) in CH2Cl2(1.0 mL) at room temperature (25 °C), and the mixture was stirred for 1 h at the same temperature. The mixture was concentrated, and a saturated aqueous NaHCO3solution was added (resulting pH ~7). The mixture was extracted with EtOAc. Organic layers were combined, dried over Na2SO4, filtered, concentrated, and purified by flash column chromatography (CH2Cl2 / MeOH = 95:5) to give compound 1e・CF3COOH (1:1) (280 mg, 38% for two steps from 5, single diastereomer) as a colorless oil. The ratio between Compound 1e and CF3COOH was determined to be 1:1 by13C NMR analysis using inverse gated1H decoupling mode (pulse program: zgig30, D1: 30 sec).

[0122] Compound 1e・CF3COOH 1H NMR (500 MHz, CD3OD): δ 7.58 (d, J = 8.5 Hz, 2H), 7.39 (d, J = 8.5 Hz, 2H), 4.47 (d, J = 11.5 Hz, 1H), 2.96 (dt, J = 13.0 Hz, 3.5 Hz, 1H), 2.72-2.65 (m, 1H), 2.65 (s, 6H), 2.13-2.07 (m, 1H), 2.02-1.93 (m, 1H), 1.86 (qd, J = 12.5 Hz, 3.8 Hz, 1H), 1.44-1.20 (m, 5H).13C NMR (125 MHz, CD3OD): δ 162.9 (q, JC,F= 34 Hz), 140.8, 133.3, 130.4, 123.2, 118.2 (q, JC,F= 291 Hz), 70.0, 55.4, 41.7, 37.3, 28.4, 26.4, 24.8, 19.9. HRMS (ESI): m / z calcd for C15H24N2Br [M+H]+311.1117, found 311.1126.

[0123] (Formation of Compound 1e (free form)) A mixture of 1e・CF3COOH (1:1) (single diastereomer, 20 mg, 0.047 mmol) and a saturated aqueous NaHCO3solution (15 mL) (resulting pH ~8) was stirred at room temperature (25 °C) for 10 min. The mixture was extracted with CH2Cl2. Organic layers were combined, washed with saturated aqueous NaCl solution, dried over Na2SO4, filtered, and concentrated to give Compound 1e (free form) (11 mg, 70%, single diastereomer) as a colorless solid.

[0124] Compound 1e (free form) [α]25D-11.5 (c 0.5, MeOH, er (based on compound 5) 99.5:0.5).1H NMR (500 MHz, CD3OD): δ 7.49 (d, J = 8.4 Hz, 2H), 7.31 (d, J = 8.4 Hz, 2H), 4.27 (d, J = 10.2 Hz, 1H), 2.38 (s, 6H), 2.42-2.33 (m, 2H), 1.99-1.89 (m, 1H), 1.89-1.79 (m, 1H), 1.79-1.65 (m, 1H), 1.43-1.24 (m, 3H), 1.24-1.08 (m, 3H).13C NMR (125 MHz, CD3OD): δ 144.6, 132.6, 130.7, 121.8, 69.7, 56.4, 44.1, 41.3, 29.3, 26.8, 25.6, 21.3.

[0125] 7. Synthesis of Compound 1f

[0126] Compound 1f was synthesized as illustrated in Scheme 9.

[0127] Scheme 9

[0128] (Synthesis of Compound S5) Compound 2 was synthesized by the same procedures as those used for the synthesis of Compound 1a. Na(OAc)3BH (21.8 g, 103 mmol) and CH3COOH (5.9 mL, 103 mmol) were added to a solution of Compound 2 (anti / syn >96:4, er 95:5, 8.00 g, 20.6 mmol) in 1,2-dichloroethane (250 mL) at 0oC, and the mixture was stirred at the same temperature for 24 h (progress was monitored by TLC and1H NMR). Further, Na(OAc)3BH (7.27 g, 34.3 mmol) and CH3COOH (5.89 mL, 103 mmol) were added, and the mixture was stirred at the same temperature for another 24 h (progress was monitored by TLC and1H NMR). Additionally, Na(OAc)3BH (7.27 g, 34.3 mmol) and AcOH (5.89 mL, 103 mmol) were added, and the mixture was stirred for another 24 h. The mixture was quenched by the addition of a saturated aqueous NaHCO3solution and extracted with CH2Cl2(100 mL x 3). The organic layers were combined, dried over Na2SO4, filtered, concentrated, and purified by flash column chromatography (hexane / EtOAc = 60:40) to give Compound S5 (4.98 g, 62%, single diastereomer) as a colorless oil.

[0129] Compound S5 1H NMR (500 MHz, CDCl3): δ 7.39 (d, J = 8.5 Hz, 2H), 7.08 (d, J = 8.5 Hz, 2H), 6.67 (d, J = 8.5 Hz, 2H), 6.59 (d, J = 8.5 Hz, 2H), 4.23 (d, J = 8.5 Hz, 1H), 3.69 (s, 3H), 3.61 (td, J = 9.5 Hz, 4.5 Hz, 1H), 2.03-2.00 (m, 1H), 1.75-1.67 (m, 2H), 1.60-1.56 (m, 1H), 1.38-1.16 (m, 3H), 1.13-1.04 (m, 1H), 0.73 (qd, J = 12.8 Hz, 3.6 Hz, 1H).13C NMR (125 MHz, CDCl3): δ 153.9, 140.0, 139.1, 131.6, 128.9, 121.0, 118.3, 118.2, 114.5, 75.5, 66.3, 55.5, 49.0, 35.4, 28.1, 25.4, 24.4. HRMS (ESI): m / z z calcd for C20H25NO2Br [M+H]+390.1063, found 390.1040.

[0130] (Synthesis of Compound 1f) A solution of ammonium cerium nitrate (CAN) (3.64 g, 6.64 mmol) in H2O (22.4 mL) to a solution of Compound S5 (589 mg, 1.51 mmol) in CH3CN (38 mL) was added at 0oC, and the mixture was stirred at the same temperature for 2 h. The mixture was diluted with water (100 mL) and extracted with EtOAc (30 mL x 3). Organic layers were combined, dried over Na2SO4, filtered, concentrated, and purified by flash column chromatography (CH2Cl2 / MeOH = 90:10) to give Compound 1f (323 mg, 75%, single diastereomer, er 96:4) as a colorless solid. The compound was crystallized from EtOAc / MeOH (99:1 (v / v)) to give Compound 1f (180 mg, single diastereomer, er 99.7:0.3) as colorless crystals. The relative stereochemistry of Compound 1f was determined by NMR analyses based on coupling constants (J values), COSY, NOESY, and HSQC.

[0131] Compound 1f [α]25D-42.8 (c 0.5, MeOH, er 99.7:0.3).1H NMR (500 MHz, CD3OD): δ 7.62 (d, J = 8.0 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 4.32 (d, J = 9.0 Hz, 1H), 3.53 (td, J = 10.0 Hz, 4.0 Hz, 1H), 2.01-1.96 (m, 1H), 1.86-1.79 (m, 1H), 1.75-1.69 (m, 1H), 1.62-1.56 (m, 1H), 1.43-1.08 (m, 4H), 0.82 (dq, J = 12.5 Hz, 3.7 Hz, 1H).13C NMR (125 MHz, CD3OD): δ 136.4, 133.3, 130.9, 124.1, 75.9, 60.9, 47.7, 36.9, 28.6, 26.1, 25.4. HRMS (ESI): m / z calcd for C13H19NOBr [M+H]+284.0645, found 284.0629. HPLC (Daicel Chiralpak AS-3, hexane / i-PrOH = 90:10, flow rate = 1.0 mL / min, λ = 220 nm): tR10.5 min (major enantiomer), 12.0 min (minor enantiomer).

[0132] 8. Synthesis of compound 1h

[0133] Compound 1h was synthesized as illustrated in Scheme 10.

[0134] Scheme 10

[0135] (Synthesis of compound S6) Compound 1f was synthesized by the same procedures as those used for the synthesis of Compound 1f. NaHCO3(444 mg, 5.28 mmol) and di-tert-butyl decarbonate (485 μL, 2.11 mmol) were added to a solution of compound 1f (single diastereomer, er 99.7:0.3, 500 mg, 1.76 mmol) in THF / H2O (1:1 (v / v), 10 mL) at 0 °C, and the mixture was stirred at room temperature (25 °C) for 5.5 h. The mixture was concentrated to remove the organic solvent and extracted with EtOAc (50 mL x 3). Organic layers were combined, dried over Na2SO4, concentrated, and purified by flash column chromatography (hexane / EtOAc = 70:30) to give Compound S6 (630 mg, 93%, single diastereomer) as a colorless oil.

[0136] Compound S61H NMR (500 MHz, CDCl3): δ 7.42 (d, J = 8.2 Hz, 2H), 7.15 (d, J = 8.2 Hz, 2H), 5.64 (brs, 1H), 4.82 (apps, 1H), 3.28 (td, J = 10.0 Hz, 4.0 Hz, 1H), 1.99-1.92 (m, 1H), 1.92-1.57 (m, 3H), 1.57-1.50 (m, 1H), 1.47-1.21 (m, 11H), 1.19-1.04 (m, 2H), 0.86-0.74 (m, 1H).13C NMR (125 MHz, CDCl3): δ 155.4, 140.4, 131.2, 129.1, 120.7, 79.6, 72.3, 56.8, 49.3, 36.2, 28.3, 26.6, 25.0, 24.4. HRMS (ESI): m / z calcd for C18H27NO3Br [M+H]+384.1169, found 384.1173.

[0137] (Synthesis of Compound S7) Ph3P (273 mg, 1.04 mmol) and diisopropyl azodicarboxylate (DIAD) (204 μL, 1.04 mmol) were added to a solution of compound S6 (single diastereomer, 100 mg, 0.26 mmol) in toluene (10 mL), at 0 °C,and the mixture was stirred at room temperature (25 °C) for 20 h. The mixture was diluted with water and extracted with EtOAc (10 mL x 3). Organic layers were combined, dried over Na2SO4, filtered, concentrated, and purified by flash column chromatography (hexane / EtOAc = 95:5) to give Compound S7 (55 mg, 58%, single diastereomer) as a colorless oil.

[0138] Compound S7 1H NMR (500 MHz, CDCl3): δ 7.43 (d, J = 8.0 Hz, 2H), 7.11 (d, J = 8.0 Hz, 2H), 5.89-5.84 (m, 1H), 5.50-5.41 (m, 1H), 4.90 (d, J = 6.5 Hz, 1H), 4.57 (t, J = 6.5 Hz, 1H), 2.52-2.41 (m, 1H), 2.02-1.94 (m, 2H), 1.79-1.66 (m, 2H), 1.55-1.20 (m, 11H).13C NMR (125 MHz, CDCl3): δ 155.4, 141.2, 131.6, 131.3, 128.0, 125.0, 120.5, 79.5, 57.7, 41.3, 28.3, 27.1, 25.0, 21.5. HRMS (ESI): m / z calcd for C18H25NO2Br [M+H]+366.1063, found 366.1070.

[0139] (Synthesis of Compound S8) Pd / C (10%, 30 mg) was added to a solution of Compound S7 (single diastereomer, 127 mg, 0.35 mmol) in MeOH (1.5 mL) at room temperature (25 °C), and the mixture was stirred under H2(balloon) for 1 h. The reaction mixture was filtered through a pad of Celite and washed with MeOH and EtOAc. The filtrate was concentrated and purified by flash column chromatography (CH6Cl2) to give Compound S8 (77 mg, 78%, single diastereomer) as a colorless oil.

[0140] Compound S8 1H NMR (500 MHz, CDCl3): δ 7.30 (t, J = 7.4 Hz, 2H), 7.24-7.13 (m, 3H), 4.88 (s, 1H), 4.41 (apps, 1H), 1.91-1.79 (m, 1H), 1.79-1.71 (m, 1H), 1.71-1.50 (m, 3H), 1.49-1.23 (m, 10H), 1.23-1.05 (m, 3H), 1.05-0.83 (m, 2H).13C NMR (125 MHz, CDCl3): δ 155.4, 142.0, 128.3, 126.8, 79.2, 59.9, 43.6, 30.1, 29.1, 28.4, 26.2, 26.13, 26.10. HRMS (ESI): m / z calcd for C18H28NO2[M+H]+290.2115, found 290.2104.

[0141] (Synthesis of Compound 1h) CF3COOH (1.0 mL) was added to a solution of Compound S8 (single diastereomer, 70 mg, 0.24 mmol) in CH2Cl2(2.0 mL) at room temperature (25 °C), and the mixture was stirred for 2 h at the same temperature. The mixture was concentrated, and a saturated aqueous NaHCO3solution was added. The mixture was extracted with EtOAc. Organic layers were combined, dried over Na2SO4, filtered, concentrated, and purified by flash column chromatography (CH2Cl2 / MeOH = 95:5) to give Compound 1h (44 mg, 98% single diastereomer, er 99.7:0.3) as a colorless oil.

[0142] Compound 1h [α]25D+5.6 (c 1.0, MeOH, er 99.7:0.3).1H NMR (500 MHz, CD3OD): δ 7.32-7.20 (m, 5H), 3.50 (d, J = 8.0 Hz, 1H), 2.03-1.96 (m, 1H), 1.83-1.76 (m, 1H), 1.69-1.58 (m, 2H), 1.58-1.49 (m, 1H), 1.38-1.22 (m, 2H), 1.22-1.08 (m, 2H), 1.01 (qd, J = 12.4 Hz, 3.5 Hz, 1H), 0.90-0.79 (m, 1H).13C NMR (125 MHz, CD3OD): δ 145.7, 129.2, 128.3, 128.0, 62.8, 46.2, 31.1, 30.8, 27.5, 27.30, 27.26. HRMS (ESI): m / z calcd for C13H20N [M+H]+190.1590, found 190.1582. HPLC (Daicel Chiralpak IC-3, hexane / i-PrOH = 80:20, flow rate = 1.0 mL / min, λ = 220 nm): tR7.0 min (major enantiomer), 8.4 min (minor enantiomer).

[0143] 9. Synthesis of compounds 1g and 1i

[0144] Compounds 1g and 1i were synthesized as illustrated in Scheme 11.

[0145] Scheme 11

[0146] (Synthesis of Compound S9) p-Anisidine (739 mg, 6.00 mmol), cyclohexanone (6.21 mL, 60 mmol), and (S)-serine (189 mg, 1.80 mmol) were sequentially added to a mixture of H2O (238 μL, 13.2 mmol) and DMSO (24 mL), 4-bromobenzaldehyde (1.22 g, 6.60 mmol), and the mixture was stirred for 72 h. The mixture was diluted with water and extracted with EtOAc (30 mL x 3). Organic layers were combined, dried over Na2SO4, filtered, and concentrated to give the Mannich reaction product, which was used for the next step without purification. The residue was dissolved in MeOH (15 mL), and NaBH4(294 mg, 7.8 mmol) was added at 0 °C. The mixture was stirred for 30 min at the same temperature. The reaction mixture was quenched with saturated aqueous NH4Cl solution and EtOAc was added. The mixture was concentrated in vacuo and solid was generated, which was filtered and washed with MeOH and water to give Compound S9 (1.05 g, 43%, single diastereomer, er 93:7) as a colorless solid. This was crystallized from hexane / EtOAc (7:3 (v / v)) to give Compound S9 (590 mg, single diastereomer, er 99.7:0.3) as a colorless solid.

[0147] Compound S9 [α]25D-24.4 (c 0.5, EtOAc, er 99.7:0.3).1H NMR (500 MHz, CDCl3): δ 7.42 (d, J = 8.5 Hz, 2H), 7.22 (d, J = 8.5 Hz, 2H), 6.67 (d, J = 9.0 Hz, 2H), 6.50 (d, J = 9.0 Hz, 2H), 4.57 (d, J = 2.5 Hz, 1H), 3.68 (s, 3H), 3.41 (td, J = 10.0 Hz, 4.5 Hz, 1H), 1.97-1.91 (m, 1H), 1.88-1.81 (m, 1H), 1.72-1.56 (m, 4H), 1.39-1.29 (m, 1H), 1.20-1.06 (m, 2H), 0.97 (qd, J = 12.4 Hz, 3.2 Hz, 1H).13C NMR (125 MHz, CDCl3): δ 152.3, 140.5, 140.0, 131.2, 129.4, 120.6, 115.3, 114.7, 71.3, 60.8, 55.6, 49.9, 36.0, 26.9, 25.4, 24.4. HRMS (ESI): m / z calcd for C20H25NO2Br [M+H]+390.1063, found 390.1048. HPLC (Daicel Chiralpak IC-3, hexane / i-PrOH = 95:5, flow rate = 0.5 mL / min, λ = 254 nm): tR32 min (major enantiomer), 36 min (minor enantiomer).

[0148] (Synthesis of Compound 1i) A solution of ammonium cerium nitrate (CAN) (1.85 g, 3.4 mmol) in H2O (9.0 mL) was added to a solution of compound S9 (300 mg, 0.77 mmol) in CH3CN (13.5 mL) at 0 °C, and the mixture was stirred at the same temperature for 2 h. The mixture was diluted with water (50 mL) and extracted with EtOAc (30 mL x 3). Organic layers were combined, dried over Na2SO4, filtered, and concentrated. CH2Cl2(10 mL) was added, and generated solid was collected by filtration to give Compound 1i (190 mg, 87%, single diastereomer, er 99.4:0.6) as a colorless solid. A 20 mmol-scale reaction: A solution of CAN (49.48 g, 90.3 mmol) in H2O (250 mL) to a solution of Compound S9 (8.00 g, 20.5 mmol) in CH3CN (350 mL), was added at 0 °C, and the mixture was stirred at the same temperature for 2 h. The mixture was diluted with water (250 mL), concentrated to remove the organic solvent, and extracted with EtOAc (200 mL x 3). Organic layers were combined, dried over Na2SO4, filtered, and concentrated. CH2Cl2was added, and generated solid was collected by filtration to give Compound 1i (5.61 g, 96%, single diastereomer) as a colorless solid.

[0149] Compound 1i [α]25D-35.7 (c 1.0, MeOH, er 99.4:0.6).1H NMR (400 MHz, CD3OD): δ 7.62 (d, J = 8.4 Hz, 2H), 7.38 (d, J = 8.8 Hz, 2H), 4.31 (d, J = 2.8 Hz, 1H), 3.24 (td, J = 10.0 Hz, 4.4 Hz, 1H), 1.94-1.83 (m, 2H), 1.79-1.71 (m, 1H), 1.71-1.62 (m, 2H), 1.42-1.20 (m, 2H), 1.12-0.98 (m, 1H), 0.82 (qd, J = 12.7 Hz, 3.3 Hz, 1H).13C NMR (100 MHz, CD3OD): δ 134.5, 132.8, 131.0, 123.9, 72.0, 60.3, 47.7, 36.6, 29.2, 26.3, 25.0. HRMS (ESI): m / z calcd for C13H19NOBr [M+H]+284.0645, found 284.0630. HPLC (Daicel Chiralpak AS-3, hexane / i-PrOH = 85:15, flow rate = 1.0 mL / min, λ = 220 nm): tR6.9 min (major enantiomer), 8.1 min (minor enantiomer).

[0150] (Synthesis of Compound S10) NaHCO3(5.16 g, 61.5 mmol) and di-tert-butyl decarbonate (5.64 mL, 24.6 mmol) were added to a solution of compound 1i (single diastereomer, er 99.4:0.6, 5.82 g, 20.5 mmol) in THF / H2O (1:1 (v / v), 70 mL) at 0 °C, and the mixture was stirred at room temperature (25 °C) for 12 h. The mixture was concentrated to remove the organic solvent and extracted with EtOAc (50 mL x 3). Organic layers were combined, dried over Na2SO4, concentrated, and, dried over Na2SO4, concentrated, and purified by flash column chromatography (hexane / EtOAc = 1:1) to give Compound S10 (6.78 g, 86%, single diastereomer) as a colorless solid.

[0151] Compound S10 1H NMR (500 MHz, CDCl3): δ 7.44 (d, J = 8.5 Hz, 2H), 7.14 (d, J = 8.5 Hz, 2H), 5.63 (d, J = 8.5 Hz, 1H), 5.11-5.03 (m, 1H), 3.25 (td, J = 10.0 Hz, 4.0 Hz, 1H), 2.00-1.91 (m, 1H), 1.75-1.55 (m, 3H), 1.55-1.03 (m, 4H), 1.44 (s, 9H), 0.83 (qd, J = 12.5 Hz, 3.7 Hz, 1H).13C NMR (125 MHz, CDCl3): δ 156.2, 139.3, 131.2, 128.5, 120.6, 80.1, 71.1, 54.5, 50.4, 34.8, 28.3, 25.3, 24.7. HRMS (ESI): m / z calcd for C18H27NO3Br [M+H]+384.1169, found 384.1184.

[0152] (Synthesis of Compound S11) A solution of DMSO (4.00 mL, 56.5 mmol) in CH2Cl2(56 mL) was added dropwise over 20 min to a solution of oxalyl chloride (2.33 mL, 27.3 mmol) in dry CH2Cl2(56 mL) at -78 °C, and the mixture was stirred for 30 min at the same temperature. To the mixture, a solution of Compound S10 (7.00 g, 18.2 mmol, single diastereomer) in CH2Cl2(56 mL) was added. The mixture was stirred for 30 min at the same temperature, and Et3N (11.2 mL, 80.2 mmol) was added. The mixture was stirred for 6 h. The mixture was diluted with water (200 mL) and extracted with CH2Cl2. Organic layers were combined, washed with brine, dried over Na2SO4, filtered, concentrated, and purified by flash column chromatography (CH2Cl2) to give Compound S11 (4.33 g, 62%, single diastereomer, er 99.6:0.4) as a colorless solid.

[0153] Compound S11 [α]25D-87.1 (c 1.0, CH2Cl2, er 99.6:0.4).1H NMR (500 MHz, CDCl3): δ 7.41-7.39 (m, 2H), 7.25-7.17 (m, 2H), 5.80 (brs, 1H), 4.82-4.73 (m, 1H), 2.88-2.76 (m, 1H), 2.38-2.20 (m, 2H), 2.15-1.79 (m, 3H), 1.78-1.49 (m, 2H), 1.44-1.23 (m, 10H).13C NMR (125 MHz, CDCl3): δ 212.5, 211.6, 155.6, 155.1, 140.8, 139.4, 131.3, 131.2, 129.9, 128.3, 121.0, 120.6, 79.6, 55.9, 54.8, 54.7, 42.6, 42.3, 32.5, 30.7, 28.2, 28.0, 26.8, 24.5, 24.4. HRMS (ESI): m / z calcd for C18H25NO3Br [M+H]+382.1012, found 382.1027. HPLC (Daicel Chiralpak IC-3, hexane / i-PrOH = 90:10, flow rate = 0.5 mL / min, λ = 220 nm): tR20.7 min (minor enantiomer), 26.8 min (major enantiomer).

[0154] (Synthesis of compound S12) p-Anisidine (1.66 g, 13.5 mmol) was added to a solution of compound S11 (single diastereomer, er 99.6:0.4, 4.30 g, 11.3 mmol) in 1,2-dichloroethane (120 mL) at 0 °C, and the mixture was stirred for 5 minutes. To the mixture, Na(OAc)3BH (7.15 g, 33.7 mmol) and CH3COOH (1.93 mL, 33.7 mmol) were added, and the mixture was stirred at the same temperature for 24 h. The mixture was quenched by addition of saturated aqueous NaHCO3solution and extracted with CH2Cl2(50 mL x 3). The organic layers were combined, dried over Na2SO4, filtered, concentrated, and purified by flash column chromatography (hexane / EtOAc = 70:30) to give the reductive amination product (5.22 g, 94%, dr 3:2) as a colorless oil. HRMS (ESI): m / z calcd for C25H34N2O3Br [M+H]+489.1747, found 489.1747. A solution of ammonium cerium nitrate (CAN) (24.7 g, 45.0 mmol) in H2O (140 mL) was added to a solution of the reductive amination product (5.00 g, 10.2 mmol) in CH3CN (200 mL) at 0 °C, and the mixture was stirred at the same temperature for 1 h. The mixture was diluted with water (300 mL) and extracted with EtOAc (100 mL x 3). Organic layers were combined, dried over Na2SO4, filtered, concentrated, and purified by flash column chromatography (CH2Cl2 / MeOH = 97:3) to give Compound S12 (90 mg, 2%, single diastereomer) as a colorless oil and a mixture of Compound S12 and S12' (3.51 g, 90%, S12 / S12' = 2:1). NMR data of Compound S12' were matched to those of Compound 5. Thus, Compound S12' was the enantiomer of Compound 5. The ketone α-position of Compound S11 might be isomerized to lead to the formation of Compound S12'.

[0155] Compound S12 1H NMR (500 MHz, CD3OD): δ 7.53 (d, J = 8.5 Hz, 2H), 7.32 (d, J = 8.5 Hz, 2H), 4.44 (d, J = 10.0 Hz, 1H), 3.13-3.08 (m, 1H), 2.12-2.05 (m, 1H), 1.98-1.81 (m, 3H), 1.68-1.29 (m, 14H).13C NMR (125 MHz, CD3OD): δ 157.9, 141.3, 133.0, 130.1, 122.6, 80.7, 56.6, 50.5, 45.4, 30.4, 28.6, 25.9, 23.0, 20.1. HRMS (ESI): m / z calcd for C18H28N2O2Br [M+H]+383.1329, found 383.1335.

[0156] Compounds S12 and S12' (2:1)1H NMR (400 MHz, CD3OD): δ 7.57-7.49 (m, 2H), 7.32 (d, J = 8.5 Hz, 2H x 2 / 3), 7.22 (d, J = 8.5 Hz, 2H x 1 / 3), 4.44 (d, J = 10 Hz, 1H x 2 / 3), 4.28 (d, J = 12.0 Hz, 1H x 1 / 3), 3.75-3.67 (m, 1H x 1 / 3), 3.18-3.01 (m, 1H x 2 / 3), 2.17-0.98 (m, 19H).

[0157] (Synthesis of Compound S13) K2CO3(4.23 g, 30.6 mmol) and 1,5-dibromopentane (4.13 mL, 30.6 mmol) were added to a solution of Compound S12 and S12' (S12 / S12' = 2:1, 3.90 g, 10.2 mmol) in CH3CN (90 mL) at room temperature (25 °C) and the mixture was refluxed at 60 °C (oil bath) for 24 h. The mixture was diluted with water and extracted with EtOAc (50 mL x 3). Organic layers were combined, dried over Na2SO4, filtered, concentrated, and purified by flash column chromatography (CH2Cl2) to give Compound S13 (700 mg, 15%, single diastereomer, er 99.8:0.2) as a colorless oil.

[0158] Compound S13 [α]25D-33.9 (c 0.5, MeOH, er 99.8:0.2).1H NMR (500 MHz, CDCl3): δ 7.38 (d, J = 8.0 Hz, 2H), 7.20 (d, J = 8.0 Hz, 2H), 5.46 (brs, 1H), 4.85-4.71 (m, 1H), 2.67-2.55 (m, 2H), 2.19-2.06 (m, 3H), 1.91-1.79 (m, 3H), 1.76-1.15 (m, 21H).13C NMR (125 MHz, CDCl3): δ 155.4, 142.8, 130.8, 129.3, 120.0, 79.0, 60.7, 56.9, 53.1, 45.5, 29.6, 28.3, 26.5, 25.6, 24.8, 24.4, 24.2, 23.8. HRMS (ESI): m / z calcd for C23H36N2O2Br [M+H]+451.1955, found 451.1957. HPLC (Daicel Chiralpak AS-3, hexane / i-PrOH = 95:5, flow rate = 1.0 mL / min, λ = 220 nm): tR5.6 min (minor enantiomer), 10.6 min (major enantiomer).

[0159] (Synthesis of compound 1g・CF3COOH) CF3COOH (2 mL) was added to a solution of compound S13 (single diastereomer, er 99.8:0.2, 700 mg, 1.55 mmol) in CH2Cl2(1 mL) at room temperature (25 °C), and the mixture was stirred for 2 h at the same temperature. The mixture was concentrated, and a saturated aqueous NaHCO3solution was added (resulting pH ~7). The mixture was extracted with EtOAc (50 mL x 3). Organic layers were combined, dried over Na2SO4, filtered, concentrated, and purified by flash column chromatography (CH2Cl2 / MeOH = 80:20) to give compound 1g・CF3COOH (1:0.8) (290 mg, 40%, single diastereomer) as a colorless solid. The ratio between Compound 1a and CF3COOH was determined by13C NMR analysis using inverse gated1H decoupling mode (pulse program: zgig30, D1: 30 sec).

[0160] Compound 1g・CF3COOH 1H NMR (500 MHz, CD3OD): δ 7.48 (d, J = 8.5 Hz, 2H), 7.31 (d, J = 8.5 Hz, 2H), 4.24 (d, J = 6.2 Hz, 1H), 2.99-2.88 (m, 2H), 2.77-2.73 (m, 1H), 2.57-2.51 (m, 2H), 2.14-2.07 (m, 1H), 1.95-1.80 (m, 2H), 1.67-1.22 (m, 12H).13C NMR (125 MHz, CD3OD): δ 162.9 (q, JC,F= 34 Hz), 144.3, 132.2, 130.0, 121.5, 118.2 (q, JC,F= 291 Hz), 64.8, 58.6, 54.4, 46.8, 27.1, 26.0, 25.0, 24.5, 24.1, 23.5. HRMS (ESI): m / z calcd for C18H28N2Br [M+H]+351.1430, found 351.1441. Compound 1g・CF3COOH was crystallized from EtOAc for X-ray crystal structural analysis. Colorless crystals, mp 180-185 °C. The X-ray crystal structure of Compound 1g・CF3COOH is illustrated in FIG. 2.

[0161] Formation of compound 1g (free form) A mixture of Compound 1g・CF3COOH (single diastereomer, 32 mg, 0.069 mmol) and a saturated aqueous NaHCO3solution (15 mL) (resulting pH ~8) was stirred at room temperature (25 °C) for 10 min. The mixture was extracted with CH2Cl2(20 mL x 3). Organic layers were combined, washed with saturated aqueous NaCl solution (15 mL), dried over Na2SO4, filtered, and concentrated to give Compound 1g (free form) (22 mg, 90%, single diastereomer) as a pale yellow solid.

[0162] Compound 1g (free form) [α]25D+1132.3 (c 1.0, MeOH, er (based on S13) 99.8:0.2).1H NMR (500 MHz, CD3OD): δ 7.42 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 8.4 Hz, 2H), 4.10 (d, J = 7.5 Hz, 1H), 2.82-2.59 (m, 2H), 2.37-2.30 (m, 1H), 2.29-2.17 (m, 2H), 2.06-1.95 (m, 1H), 1.91-1.74 (m, 2H), 1.74-1.55 (m, 3H), 1.55-1.17 (m, 10H).13C NMR (125 MHz, CD3OD): δ 146.3, 131.9, 130.5, 120.9, 63.3, 58.4, 54.4, 27.6, 26.1, 25.4, 25.3, 25.2, 24.9.

[0163] Example 2 (Evaluations of Catalyst Systems) As illustrated in following Scheme 12, we evaluated the use of 1a-1i in the presence or absence of acids in catalysis of the Mannich reaction of β-ketophosphonate 7a with imine 8a to afford γ-position-selective Mannich reaction product 9a. The results of evaluations are illustrated in Table 1.

[0164] Scheme 12 Imine 8a (0.25 mmol, 1.0 equiv) and diethyl (2-oxopropyl) phosphonate (7a) (0.75 mmol) were added to a mixture of catalyst system (as indicated, equiv relative to 8a) in toluene (1.65 mL), at room temperature (25 °C), and the mixture was stirred at the same temperature. The reaction was monitored by TLC analyses. At the indicated time, a small portion of the mixture was taken out, diluted with CDCl3, and analyzed by1H NMR to determine the yield of 9a. After the1H NMR analysis, the remaining reaction mixture was directly purified by flash column chromatography (EtOAc) to give Compound 9a. The er of Compound 9a was determined by HPLC analysis.

[0165] Table 1

[0166] Among the conditions tested, the reactions catalyzed by catalyst system containing 1a-1e, ent-1a and 1g afforded 9a with high enantioselectivities (Table 1, entry 1-12). The reactions where the compound was either in acid addition salt or the compound in the free form used with dibenzyl phosphate, afforded 9a with high yields (Table 1, entry 2-12). In particular, the reactions in the presence of compound 1a・CF3COOH with dibenzyl phosphate or of compound 1a with CF3COOH and dibenzyl phosphate at room temperature (25 °C) afforded 9a in higher yields with higher enantioselectivities (Table 1, entry 4 and 6). On the other hand, in the reactions catalyzed by catalyst system containing 1f, and 1i, the yields of 9a were 0% (Table 1, entry 13-14. Comparative examples).

[0167] Example 3 (Evaluations of reactions of Compounds 7 and 8 to afford Compound 9) As illustrated in following Scheme 13, using compound 1a・CF3COOH with dibenzyl phosphate as the catalyst system, the scope of the γ-position-selective Mannich reactions of β-ketophosphonates was evaluated.

[0168] Scheme 13

[0169] (Synthesis of racemic standards of 9) Pyrrolidine (0.1 mmol, 0.2 equiv) and CH3COOH (0.1 mmol, 0.2 equiv) were added to a mixture of (2-oxopropyl)phosphonate 7 (1.5 mmol, 3.0 equiv) and imine 8 (0.5 mmol, 1.0 equiv) in CHCl3(1.0 mL) at room temperature (25 °C), and the mixture was stirred at 50 °C (oil bath) (monitored by TLC and / or1H NMR). After being cooled to room temperature, the mixture was directly purified by flash column chromatography (EtOAc) to give Compounds (±)-9.

[0170] (Enantioselective reactions of Compound 7 and Compound 8 to afford Compound 9 catalyzed by Compound 1a (catalyst) and dibenzyl phosphate) Imine 8 (0.25 mmol, 1.0 equiv) was added to a mixture of Compound 1a-CF3COOH (1:1) (0.075 mmol, 0.3 equiv) and dibenzyl phosphate (0.075 mmol, 0.3 equiv) in toluene (1.65 mL) at room temperature (25 °C) followed by (2-oxopropyl)phosphonate 7 (0.75 mmol, 3.0 equiv), and the mixture was stirred at the same temperature until the imine was completely or mostly consumed (formation of 9 was monitored by1H NMR analyses). For the1H NMR analysis, a portion of the reaction mixture was taken out and diluted with CDCl3. The1H NMR yield of Compound 9 was determined based on the ratio between remaining Compound 8 (imine) and Compound 9 (formed product) before purification. With the exception of the formation of Compound 9, no other products were observed to the degree that affects the determination of the yield of Compound 9. The mixture was directly purified by flash column chromatography (EtOAc) to give Compound 9. The enantiomer ratio (er) of Compound 9 was determined by HPLC analysis except Compounds 9e and 9i. The absolute configuration of the major enantiomer of Compound 9a obtained from the reaction of Compounds 7a and 8a in the presence of Compound 1a and dibenzyl phosphate was determined to be S based on the analogy to that of Compound 11c obtained in the presence of Compound 1a and dibenzyl phosphate matched to previously reported (S)-11c. The absolute configuration of the major enantiomer of Compound 9g obtained from the reaction of Compounds 7a and 8a in the presence of Compound 1a and dibenzyl phosphate was determined to be S by X-ray crystal structural analysis. Absolute configurations of Compound 9 other than Compounds 9a and 9g were determined by analogy.

[0171] [b] A 1.0 mmol-scale reaction. [c] Determined after derivatization. [d] Reaction at 40 °C.

[0172] Compound 9a General procedure, 72 h, flash column chromatography (EtOAc), 78.8 mg (84%, er 96:4), colorless solid. [α]D24-30.4 (c = 1.0, MeOH, er 96:4). Lit. [α]D24-31.9 (c =1.0, THF, er 94:6).1H and13C NMR data were in agreement with previously reported data.1H NMR (500 MHz, CDCl3) δ 7.32-7.29 (m, 1H), 7.20-7.15 (m, 2H), 7.02 (d, J = 8.1 Hz, 2H), 6.21 (d, J = 8.1 Hz, 1H), 5.22 (td, J = 8.1 Hz, 3.8 Hz, 1H), 4.17-4.09 (m, 4H), 3.79 (dd, J = 18.0 Hz, 8.1 Hz, 1H), 3.22-3.10 (m, 3H), 1.33 (t, J = 7.1 Hz, 3H), 1.31 (t, J = 7.1 Hz, 3H).13C NMR (125 MHz, CDCl3): δ 199.80, 199.75, 151.2, 129.6, 126.0, 125.3, 121.2, 119.0, 63.23, 63.17, 63.01, 62.96, 53.2, 46.9, 43.9, 42.9, 16.28, 16.25, 16.24, 16.20. HRMS (ESI): m / z calcd for C14H21O7NPS [M+H]+378.0771, found 378.0769. HPLC (Daicel Chiralpak IC-3, hexane / i-PrOH = 80:20, flow rate = 1.0 mL / min, λ = 220 nm): tR(minor enantiomer) = 56 min, tR(major enantiomer) = 80 min.

[0173] Compound 9b General procedure, 72 h, flash column chromatography (EtOAc), 73.2 mg (75%, er 96:4), colorless oil. [α]D24-30.5 (c = 1.0, MeOH, er 96:4).1H NMR (500 MHz, CDCl3) δ 7.09 (d, J = 8.5 Hz, 1H), 6.96 (s, 1H), 6.90 (d, J = 8.5 Hz, 1H), 6.04 (d, J = 8.3 Hz, 1H), 5.17 Hz (td, J = 8.3 Hz, 3.5 Hz, 1H), 4.19-4.08 (m, 4H), 3.77 (dd, J = 18.1 Hz, 8.3 Hz, 1H), 3.22-3.09 (m, 3H), 2.30 (s, 3H), 1.33 (t, J = 7.3 Hz, 3H), 1.31 (t, J = 7.3 Hz, 3H).13C NMR (125 MHz, CDCl3): δ 199.81, 199.76, 149.1, 135.1, 130.2, 126.3, 120.7, 118.7, 63.2, 63.1, 63.0, 62.9, 53.2, 47.0, 43.9, 42.9, 25.3, 20.8, 16.28, 16.26, 16.23, 16.21. HRMS (ESI): m / z calcd for C15H23O7NPS [M+H]+392.0927, found 392.0921. HPLC (Daicel Chiralpak IC-3, hexane / i-PrOH = 80:20, flow rate = 1.0 mL / min, λ = 220 nm): tR(minor enantiomer) = 56 min, tR(major enantiomer) = 95 min.

[0174] Compound 9c General procedure, 48 h, flash column chromatography (EtOAc), 80.7 mg (78%, er 97:3), colorless solid. [α]D24-35.4 (c = 1.0, MeOH, er 97:3).1H NMR (500 MHz, CDCl3) δ 7.27-7.24 (m, 1H), 7.19-7.17 (m, 1H), 6.95 (d, J = 8.5 Hz, 1H), 6.62 (d, J = 8.0 Hz, 1H), 5.18 (td, J = 8.0 Hz, 4.0 Hz, 1H), 4.17-4.08 (m, 4H), 3.77 (dd, J = 18.3 Hz, 8.0 Hz, 1H), 3.24-3.09 (m, 3H), 1.31 (t, J = 7.1 Hz, 3H), 1.30 (t, J = 7.1 Hz, 3H).13C NMR (125 MHz, CDCl3): δ 199.42, 199.38, 149.7, 130.4, 129.6, 126.1, 123.0, 120.3, 63.3, 63.2, 63.1, 63.0, 52.7, 46.9, 43.6, 42.6, 16.23, 16.22, 16.19, 16.18. HRMS (ESI): m / z calcd for C14H20O7NClPS [M+H]+412.0381, found 412.0357. HPLC (Daicel Chiralpak IC-3, hexane / i-PrOH = 80:20, flow rate = 1.0 mL / min, λ = 220 nm): tR(minor enantiomer) = 36 min, tR(major enantiomer) = 56 min.

[0175] Compound 9d General Procedure, 48 h, flash column chromatography (EtOAc), 85.9 mg (84%, er 97:3), white solid. [α]D24-40.4 (c = 1.0, MeOH, er 97:3).1H NMR (500 MHz, CDCl3) δ 6.94 (d, J = 9.0 Hz, 1H), 6.82 (dd, J = 9.0 Hz, 2.7 Hz, 1H), 6.68 (d, J = 2.7 Hz, 1H), 6.24 (d, J = 8.4 Hz, 1H), 5.16 (td, J = 8.4 Hz, 3.9 Hz, 1H), 4.17-4.07 (m, 4H), 3.78 (dd, J = 18.3 Hz, 8.4 Hz, 1H), 3.77 (s, 3H), 3.21-3.09 (m, 3H), 1.31 (t, J = 7.0 Hz, 3H), 1.29 (t, J = 7.0 Hz, 3H).13C NMR (125 MHz, CDCl3): δ 199.81, 199.76, 156.7, 144.9, 122.0, 119.9, 114.8, 110.9, 63.2, 63.1, 63.0, 62.9, 55.7, 53.2, 47.0, 43.7, 42.7, 16.24, 16.19, 16.15. HRMS (ESI): m / z calcd for C15H23O8NPS [M+H]+408.0877, found 408.0875. HPLC (Daicel Chiralpak IC-3, hexane / i-PrOH = 80:20, flow rate = 1.0 mL / min, λ = 220 nm): tR(minor enantiomer) = 69 min, tR(major enantiomer) = 106 min.

[0176] Compound 9e General procedure, 48 h, flash column chromatography (EtOAc), 89.9 mg (85%, er (determined after transformation to 9e-OH) 96:4), colorless oil.1H NMR (500 MHz, CDCl3) δ 8.20 (dd, J = 9.0 Hz, 2.5 Hz, 1H), 8.13 (d, J = 2.5 Hz, 1H), 7.18 (d, J = 9.0 Hz, 1H), 6.79 (d, J = 8.6 Hz, 1H), 5.33-5.27 (m, 1H), 4.19-4.10 (m, 4H), 3.85 (dd, J = 18.2 Hz, 7.8 Hz, 1H), 3.28-3.12 (m, 3H), 1.33 (t, J = 7.2 Hz, 3H), 1.32 (t, J = 7.2 Hz, 3H).13C NMR (125 MHz, CDCl3): δ 199.01, 198.97, 155.6, 144.4, 125.0, 122.7, 122.3, 120.1, 63.42, 63.37, 63.22, 63.16, 52.7, 46.8, 43.7, 42.7, 16.24, 16.22, 16.19, 16.17. HRMS (ESI): m / z calcd for C14H20O9N2PS [M+H]+423.0622, found 424.0668.

[0177] (Transformation of compound 9e-OH to compound 9e) NaBH4(38 mg, 0.10 mmol) was added to a solution of Compound 9e (42.2 mg, 0.1 mmol in MeOH (200 μL) at 0 °C, and the mixture was stirred for 45 min at the same temperature. The mixture was purified by preparative TLC (EtOAc) to afford Compound 9e-OH (7.0 mg, 17%, dr 2:1, a mixture of the diastereomers was isolated) as a colorless oil.

[0178] Compound 9e-OH A mixture of two diastereomers, dr 2:1, er major diastereomer 93:7, er minor diastereomer 96:4. The higher er value was used for the er of Compound 9e as isomerization of Compound 9e may occur under the conditions used in the formation of Compound 9e-OH.1H NMR (500 MHz, CDCl3) δ 8.22 (dd, J = 9.0 Hz, 2.0 Hz, 1H × 2 / 3), 8.20 (dd, J = 9.0 Hz, 2.0 Hz, 1H × 1 / 3), 8.17 (d, J = 2.0 Hz, 1H × 1 / 3), 8.12-8.10 (m, 1H × 2 / 3), 7.20 (d, J = 9.0 Hz, 1H × 2 / 3), 7.17 (d, J = 9.0 Hz, 1H × 1 / 3), 6.96-6.88 (m, 1H), 5.15 (td, J = 8.0 Hz, 2.5 Hz, 1H × 2 / 3), 5.13-5.07 (m, 1H × 1 / 3), 4.43-4.35 (m, 1H × 1 / 3), 4.25-4.01 (m, 1H × 2 / 3 + 4H), 2.49-1.95 (m, 4H), 1.39-1.22 (m, 6H).13C NMR (125 MHz, CDCl3): δ 156.1, 155.2, 144.42, 144.38, 124.94, 124.88, 123.8, 122.7, 122.4, 122.3, 120.4, 120.2, 65.20, 65.17, 63.39, 63.35, 62.53, 62.50, 62.48, 62.45, 62.4, 62.3, 55.21, 55.20, 55.11, 55.09, 41.3, 41.2, 39.5, 39.3, 34.0, 33.9, 32.9, 32.8, 16.37, 16.34, 16.31, 16.29, 16.24. HRMS (ESI): m / z calcd for C14H22O9N2PS [M+H]+425.0778, found 425.0782. HPLC (Daicel Chiralpak IC-3, hexane / i-PrOH = 85:15, flow rate = 0.8 mL / min, λ = 220 nm): tR(major diastereomer, minor enantiomer) = 50 min, tR(major diastereomer, major enantiomer) = 82 min, tR(minor diastereomer, minor enantiomer) = 74 min, tR(minor diastereomer, major enantiomer) = 109 min.

[0179] Compound 9f General procedure, 168 h, flash column chromatography (EtOAc), 84.5 mg (79%, er 95:5), white solid. [α]D24-44.1 (c = 1.0, MeOH, er 95:5).1H NMR (500 MHz, CDCl3) δ 7.83 (d, J = 8.3 Hz, 1H), 7.78 (d, J = 8.9 Hz, 1H), 7.59 (d, J = 8.3 Hz, 1H), 7.56-7.51 (m, 1H), 7.49-7.45 (m, 1H), 7.09 (d, J = 8.9 Hz, 1H), 6.50 (d, J = 6.3 Hz, 1H), 5.81 (ddd, J = 10.6 Hz, 6.3 Hz, 2.0 Hz, 1H), 4.16-4.06 (m, 4H), 4.00 (dd, J = 18.7 Hz, 10.6 Hz, 1H), 3.24-3.11 (m, 2H), 3.08 (dd, J = 18.7 Hz, 2.0 Hz, 1H), 1.26 (t, J = 7.1 Hz, 6H).13C NMR (125 MHz, CDCl3): δ 199.7, 199.6, 149.1, 131.1, 130.7, 129.21, 129.18, 128.0, 125.7, 122.0, 118.4, 114.0, 62.93, 62.88, 62.85, 62.79, 51.4, 47.0, 43.2, 42.2, 16.22, 16.20, 16.18, 16.15. HRMS (ESI): m / z calcd for C18H23O7NPS [M+H]+428.0927, found 428.0922. HPLC (Daicel Chiralpak IC-3, hexane / i-PrOH = 80:20, flow rate = 0.8 mL / min, λ = 220 nm): tR(minor enantiomer) = 61 min, tR(major enantiomer) = 90 min.

[0180] Compound 9g General procedure (imine not fully consumed), 10 days (1H NMR yield 68%), flash column chromatography (EtOAc), 59.0 mg (58%, er 94:6), colorless solid. [α]D24-14.7 (c = 1.0, MeOH, er 94:6).1H NMR (500 MHz, CDCl3) δ 7.08 (d, J = 7.8 Hz, 1H), 6.92 (d, J = 7.8 Hz, 1H), 5.52 (d, J = 5.6 Hz, 1H), 5.25 (ddd, J = 10.3 Hz, 5.6 Hz, 2.5 Hz, 1H), 4.20-4.10 (m, 4H), 3.86 (dd, J = 18.5 Hz, 10.3 Hz, 1H), 3.23 (dd, J = 22.5 Hz, 13.5 Hz, 1H), 3.13 (dd, J = 22.5 Hz, 13.5 Hz, 1H), 2.93 (dd, J = 18.5 Hz, 2.5 Hz, 1H), 2.24 (s, 3H), 2.23 (s, 3H), 1.33 (t, J = 7.1 Hz, 6H).13C NMR (125 MHz, CDCl3): δ 199.40, 199.35, 150.0, 132.5, 130.7, 127.1, 125.9, 120.2, 62.93, 62.88, 62.82, 62.77, 51.7, 46.4, 43.5, 42.5, 18.6, 16.31, 16.29, 16.27, 16.24, 15.3. HRMS (ESI): m / z calcd for C16H25O7NPS [M+H]+406.1084, found 406.1092. HPLC (Daicel Chiralpak IC-3, hexane / i-PrOH = 80:20, flow rate = 1.0 mL / min, λ = 220 nm): tR(minor enantiomer) = 62 min, tR(major enantiomer) = 71 min. Compound 9g was crystallized from CHCl3. Colorless crystals, mp 95-100 °C, er 96:4. HPLC (Daicel Chiralpak IC-3, hexane / i-PrOH = 80:20, flow rate = 1.0 mL / min, λ = 220 nm): tR(minor enantiomer) = 64 min, tR(major enantiomer) = 75 min. The X-ray crystal structure of compound 9g is illustrated in FIG. 3.

[0181] Compound 9h General procedure (imine not fully consumed), 14 days (1H NMR yield 41%), flash column chromatography (EtOAc), 30.1 mg (28%, er 92:8), colorless oil. [α]D24-20.0 (c = 1.0, MeOH, er 92:8).1H NMR (500 MHz, CDCl3) δ 6.26 (d, J = 2.4 Hz, 1H), 6.16 (d, J = 2.4 Hz, 1H), 5.63 (d, J = 6.5 Hz, 1H), 5.21 (ddd, J = 10.1 Hz, 6.5 Hz, 2.5 Hz, 1H), 4.20-4.08 (m, 4H), 3.80 (s, 6H), 3.78 (s, 3H), 3.66 (dd, J = 17.8 Hz, 10.1 Hz, 1H), 3.22-3.07 (m, 3H), 1.344 (t, J = 7.0 Hz, 3H), 1.339 (t, J = 7.0 Hz, 3H).13C NMR (125 MHz, CDCl3): δ 200.14, 200.09, 161.0, 156.9, 152.3, 102.1, 95.8, 95.2, 62.9, 62.82, 62.80, 62.75, 55.9, 55.6, 50.6, 46.3, 43.6, 42.6, 16.32, 16.30, 16.27, 16.25. HRMS (ESI): m / z calcd for C16H25O9NPS [M+H]+438.0982, found 438.1030. HPLC (Daicel Chiralpak IC-3, hexane / i-PrOH = 70:30, flow rate = 1.0 mL / min, λ = 220 nm): tR(minor enantiomer) = 49 min, tR(major enantiomer) = 70 min.

[0182] Compound 9i General procedure, 48 h, flash column chromatography (EtOAc), 106.9 mg (80%, er (determined after transformation to 9i-OH) 95:5), colorless oil.1H NMR (500 MHz, CDCl3) δ 7.68-7.67 (m, 1H), 7.29-7.28 (m, 1H), 6.97 (d, J = 8.4 Hz, 1H), 5.23-5.17 (m, 1H), 4.16-4.08 (m, 4H), 3.76 (dd, J = 18.3 Hz, 7.8 Hz, 1H), 3.24-3.09 (m, 3H), 1.31 (t, J = 7.0 Hz, 6H).13C NMR (125 MHz, CDCl3): δ 199.1, 199.0, 147.3, 135.6, 128.2, 125.0, 117.7, 113.6, 63.4, 63.3, 63.2, 63.1, 52.7, 47.1, 43.5, 42.5, 16.26, 16.25, 16.22, 16.20. HRMS (ESI): m / z calcd for C14H19O7NBr2PS [M+H]+533.8981, found 533.9040.

[0183] (Transformation of Compounds 9i to 9i-OH) NaBH4(38 mg, 0.1 mmol) was added to a solution of Compound 9i (53.5 mg, 0.1 mmol in MeOH (200 μL), at 0 °C, and the mixture was stirred for 45 min at the same temperature. The mixture was purified by preparative TLC (EtOAc) to afford Compound 9i-OH (11 mg, 21%, dr 2:1, a mixture of the diastereomers was isolated) as a colorless oil.

[0184] Compound 9i-OH A mixture of two diastereomers, dr 2:1, er major diastereomer 95:5, er minor diastereomer 95:5.1H NMR (500 MHz, CDCl3): δ 7.71-7.69 (m, 1H), 7.32-7.30 (m, 1H × 1 / 3), 7.26-7.23 (m, 1H × 2 / 3), 6.87 (d, J = 8.4 Hz, 1H × 2 / 3), 6.80 (d, J = 6.0 Hz, 1H × 1 / 3), 5.06-5.02 (m, 1H × 2 / 3), 4.99-4.95 (m, 1H × 1 / 3), 4.35-4.02 (m, 5H), 2.38-1.92 (m, 5H), 1.37-1.30 (m, 6H).13C NMR (125 MHz, CDCl3): δ 147.9, 147.2, 135.52, 135.46, 128.6, 128.2, 126.2, 124.8, 117.7, 117.6, 114.0, 113.8, 65.02, 64.98, 63.33, 63.29, 62.47, 62.42, 62.40, 62.35, 55.20, 55.17, 55.1, 41.6, 41.4, 40.0, 39.9, 34.1, 33.8, 33.0, 32.7, 16.4, 16.3. HRMS (ESI): m / z calcd for C14H21O7NBr2PS [M+H]+535.9138, found 535.9178. HPLC (Daicel Chiralpak IC-3, hexane / i-PrOH = 92:8, flow rate = 0.8 mL / min, λ = 220 nm): tR(major diastereomer, minor enantiomer) = 79 min, tR(major diastereomer, major enantiomer) = 84 min, tR(minor diastereomer, minor enantiomer) = 106 min, tR(minor diastereomer, major enantiomer) = 115 min.

[0185] Compound 9j General procedure, 12 days, flash column chromatography (EtOAc), 103.0 mg (89%, er 93:7), colorless solid. [α]D24-29.0 (c = 1.0, MeOH, er 93:7). Lit. [α]D24-51.4 (c = 1.0, CHCl3, er 95.7:4.3).1H and13C NMR data were in agreement with previously reported data in V. Bethi, F. Tanaka, Org. Lett. 2022, 24,6711. HRMS (ESI): m / z calcd for C18H27O9NPS [M+H]+464.1139, found 464.1138. HPLC (Daicel Chiralpak IF-3, hexane / i-PrOH = 80:20, flow rate = 1.0 mL / min, λ = 220 nm): tR(major enantiomer) = 35 min, tR(minor enantiomer) = 51 min.

[0186] Compound 9k General procedure, 48 h, flash column chromatography (EtOAc), 35.9 mg (41%, er 95:5), white solid. [α]D24-18.3 (c = 1.0, MeOH, er 95:5).1H NMR (500 MHz, CDCl3) δ 7.35-7.29 (m, 1H), 7.20-7.16 (m, 2H), 7.04 (d, J = 8.1 Hz, 1H), 5.90 (d, J = 8.3 Hz, 1H), 5.22 (td, J = 8.3 Hz, 3.7 Hz, 1H), 3.82 (dd, J = 18.0 Hz, 8.3 Hz, 1H), 3.80 (d, J = 12.0 Hz, 3H), 3.78 (d, J = 12.0 Hz, 3H), 3.20 (dd, J = 23.0 Hz, 13.5 Hz, 1H), 3.15 (dd, J = 23.0 Hz, 13.3 Hz, 1H), 3.14 (dd, J = 18.0 Hz, 3.7 Hz, 1H).13C NMR (125 MHz, CDCl3): δ 199.63, 199.58, 151.2, 129.7, 126.0, 125.4, 120.9, 119.2, 53.48, 53.43, 53.28, 53.24, 46.8, 42.9, 41.9. HRMS (ESI): m / z calcd for C12H17O7NPS [M+H]+350.0458, found 350.0490. HPLC (Daicel Chiralpak IC-3, hexane / i-PrOH = 80:20, flow rate = 0.8 mL / min, λ = 220 nm): tR(minor enantiomer) = 28 min, tR(major enantiomer) = 40 min.

[0187] Example 4 (Evaluations of Mannich reactions of β-ketocarbonyl compounds in the presence of the catalyst system containing compound 1a) To further understand the features of the catalysis by Compound 1a, reactions of β-ketocarbonyl compounds other than β-ketophosphonates with Compound 8a (imine) under the conditions used for the formation of Compound 9 were evaluated. The reaction is illustrated in Scheme 14.

[0188] Scheme 14

[0189] (Synthesis of racemic standards of 11) Racemic standards of Compound 11 were synthesized using pyrrolidine-acetic acid (1:1) as catalyst by the reported procedures as the same procedure to form (±)-9 as described above.

[0190] (General procedure of the enantioselective reactions of ketones and Compound 8a to afford Compound 11 in the presence of Compound 1a and dibenzyl phosphate) Compound 8a (0.25 mmol, 1.0 equiv) was added to a mixture of Compound 1a-CF3COOH (1:1) (0.075 mmol, 0.3 equiv) and dibenzyl phosphate (0.075 mmol, 0.3 equiv) in toluene (1.65 mL), at room temperature (25 °C) followed by ketone (CH3(=O)R) (0.75 mmol, 3.0 equiv), and the mixture was stirred at the same temperature until the imine was completely or mostly consumed (formation of 11 was monitored by1H NMR analyses). For the1H NMR analysis, a portion of the reaction mixture was taken out and diluted with CDCl3. The1H NMR yield of Compound 11 was determined based on the ratio among remaining imine 8a, γ-position reaction product 11, and the α-position reaction product (if any) before purification. The mixture was directly purified by flash column chromatography to give Compound 11. For Compound 11a, enantiomer ratio (er) was determined after transformation to derivative 11a-NOH. For Compounds 11b and 11c, the er was determined by HPLC analysis. [b] Determined after derivatization.

[0191] In the reactions of β-ketocarbonyl compounds other than β-ketophosphonates with Compound 8a (imine) under the conditions used for the formation of Compound 9, γ-position reaction products which are Compounds 11a-11h, respectively, were obtained, and no formation of α-position reaction products was observed.

[0192] Compound 11a General procedure, 48 h, flash column chromatography (CH2Cl2 / EtOAc = 90:10), 59.2 mg (70%, keto form / enol form = 2:1, er (determined after transformation to 11a-NOH) 97:3).1H and13C NMR data were in agreement with previously reported data in V. Bethi, F. Tanaka, Org. Lett. 2022, 24,6711.

[0193] (Transformation of Compound 11a to Compound 11a-NOH) Compound 11a (35.0 mg, 0.10 mmol) was transformed to Compound 11a-NOH by the reported procedure in V. Bethi, F. Tanaka, Org. Lett. 2022, 24,6711. 11a-NOH (23.3 mg, 83%, er 97:3) was obtained as a colorless solid.

[0194] Scheme 15

[0195] Compound 11a-NOH [α]D24-30.0 (c = 0.4, MeOH, er 97:3). Lit. [α]D24-2.1 (c = 1.0, CHCl3, er 95.6:4.4).1H and13C NMR data were in agreement with previously reported data in V. Bethi, F. Tanaka, Org. Lett. 2022, 24,6711. HPLC (Daicel Chiralpak IC-3, hexane / i-PrOH = 80:20, flow rate = 0.8 mL / min, λ = 220 nm): tR(minor enantiomer) = 33 min, tR(major enantiomer) = 46 min.

[0196] Compound 11b General procedure, 72 h, flash column chromatography (CH2Cl2 / EtOAc = 90:10), 58.8 mg (70%, er 92:8), colorless solid.1H NMR (500 MHz, (CD3)2SO): δ 8.73 (s, 1H), 7.40-7.32 (m, 2H), 7.28-7.22 (m, 1H), 7.11-7.09 (m, 1H), 5.15 (dd, J = 8.8 Hz, 3.8 Hz, 1H), 4.63 (d, J = 15.0 Hz, 1H), 4.59 (d, J = 15.0 Hz, 1H), 3.47 (dd, J = 18,5 Hz, 8.8 Hz, 1H), 3.35 (dd, J = 18.5 Hz, 3.8 Hz, 1H), 3.12 (s, 3H).13C NMR (125 MHz, (CD3)2SO): δ 198.1, 151.6, 130.5, 128.1, 126.2, 122.9, 119.2, 64.7, 52.2, 49.5, 42.8. HPLC (Daicel Chiralpak IC-3, hexane / i-PrOH = 70:30, flow rate = 0.8 mL / min, λ = 220 nm): tR(minor enantiomer) = 51 min, tR(major enantiomer) = 74 min.

[0197] Compound 11c General procedure, 144 h,1H NMR yield of 11c 57%,1H NMR yield of the corresponding α-position reaction product 41%. Compound 11c was purified by preparative TLC (hexane / EtOAc = 80 / 20), er 97:3, colorless oil. [α]D24-19.5 (c = 0.4, MeOH, er 97:3). Lit. [α]D24-59.3 (c = 1.0, CHCl3, er 98.9:1.1).1H and13C NMR data of Compound 11c were in agreement with previously reported data in V. Bethi, F. Tanaka, Org. Lett. 2022, 24,6711. HPLC (Daicel Chiralpak IC-3, hexane / i-PrOH = 80:20, flow rate = 0.8 mL / min, λ = 220 nm): tR(major enantiomer) = 32 min, tR(minor enantiomer) = 43 min.

[0198] It was confirmed that the target compounds were obtained based on1H and13C NMR data of Compounds 11d to 11h.

[0199] Example 4 (Evaluation of Mannich-aza-Michael reaction to afford Compound 12)

[0200] Compound 12

[0201] The Mannich-aza-Michael reaction shown below was performed using the catalyst system containing 1a. The reaction product (Compound 12) is known (Org. Lett. 2013, 15, 6090; other catalysts were used to form this product with dr >19:1, 95% ee).

[0202] Scheme 16

[0203] To a mixture of 1a-CF3COOH (1:1) (10.5 mg, 0.03 mmol) in toluene (660 μL), imine (18.3 mg, 0.1 mmol) was added at room temperature (25 °C) followed by 3-hepten-2-one (39.6 μL, 0.3 mmol), and the mixture was stirred at the same temperature for 72 h (formation of the product was monitored by1H NMR analyses;1H NMR yield of the desired product >95%). For the1H NMR analysis, a portion of the reaction mixture was taken out and diluted with CDCl3. The1H NMR yield of the product was determined based on the ratio between the remaining imine and the desired product before purification (the uncyclized Mannich product was not detected at 72 h). The mixture was directly purified by flash column chromatography (hexane / EtOAc = 70:30) to give the product (Compound 12). The enantiomer ratio (er) of the product was determined by HPLC analysis. HPLC (Daicel Chiralpak IC3, hexane / i-PrOH = 90:10, flow rate = 0.8 mL / min, λ = 220 nm): tR (major enantiomer) = 21 min, tR (minor enantiomer) = 36 min.

[0204] According to the present disclosure, novel 1,3-diamine derivatives and their applications, including catalytic uses, are provided.

Claims

1. A compound represented by a formula (I) or a salt thereof wherein R1and R2are independently selected from the group consisting of an alkyl, an alkenyl, an alkynyl, a heteroalkyl, a heteroalkenyl, or a heteroalkynyl, which may be substituted with one or more selected from the group consisting of an aryl and a heteroaryl, or R1and R2together form - (CH2)p-, and the - (CH2)p- forms a ring in combination with the nitrogen atom that the R1and the R2are both attached to, wherein p is an integer from 2 to 8, and the - (CH2)p- may be interrupted by one to three hetero atom(s) and may be substituted with one or more selected from the group consisting of an alkyl, an aryl, and a heteroaryl; R3is independently selected from the group consisting of an alkyl, and an aryl, or two adjacent R3s may form a ring with carbon atoms they are attached to; R4is independently selected from the group consisting of a halogen atom, an alkyl, an alkoxy, a cyano, a nitro, and an acylamido, or two adjacent R4s may form a ring in combination with carbon atoms they are attached to; m is an integer from 0 to 8; and n is an integer from 0 to 5.

2. The compound or the salt thereof according to claim 1, wherein the compound is represented by formula (1-1) or (1-2) wherein R1, R2, R3, R4, m, and n are as defined in claim 1.

3. A catalyst comprising a compound or a salt thereof according to claim 1 or 2.

4. The catalyst according to claim 3 wherein it is used in a Mannich reaction.

5. A method of preparing a compound or a salt thereof according to claim 1 comprising: converting an -NHPMP moiety of a compound represented by a formula (II) to an amino group; and introducing the amino group by reductive amination of a carbonyl group of the compound represented by the formula (II), followed by converting the introduced amino group to a tertiary amino group to form an -NR1R2moiety, wherein R1, and R2are as defined in claim 1 wherein PMP is a p-methoxyphenyl group, and R3, R4, m, and n are as defined in claim 1.

6. A method of preparing a Mannich product, comprising: reacting a compound represented by formula (VIII) with a compound represented by formula (VII), in the presence of a compound represented by the formula (I) according to claim 1 wherein Rcis a hydrogen atom or monovalent carbon atom which may be substituted with a -P(=O)(ORd)(ORe), a -C(=O)Rd, a -S(=O)2Rd, a -C(=O)ORd, or a -C(=O)NRfRg, wherein Rdis an alkyl, Reis an alkyl, Rfis a hydrogen atom or an alkyl, and Rgis a hydrogen atom or an alkyl; wherein Rais independently selected from the group consisting of an alkyl, a halogen atom, an alkoxy, and a nitro, or two adjacent Ras may form a ring in combination with carbon atoms they are attached to; s is an integer of 0 to 4; and Rbis a hydrogen atom or an alkoxycarbonyl.

7. The method of preparing a Mannich product according to claim 6, comprising: reacting the compound represented by the formula (VIII) with the compound represented by the formula (VII), in the presence of the compound represented by the formula (1-1) according to claim 2 to obtain a compound represented by formula (9-1), or in the presence of the compound represented by the formula (1-2) according to claim 2 to obtain a compound represented by formula (9-2) wherein Ra, Rb, Rcand s are as defined in claim 6.

8. The method of preparing a Mannich product according to claim 6, comprising: reacting the compound represented by the formula (VIII) with the compound represented by the formula (VII’) to obtain a compound represented by formula (9-3) wherein Rhis a hydrogen atom, a -P(=O)(ORd)(ORe), a -C(=O)Rd, a -S(=O)2Rd, a -C(=O)ORd, a -C(=O)NRfRg, or a monovalent hydrocarbon group which may be substituted with a -P(=O)(ORd)(ORe), a -C(=O)Rd, a -S(=O)2Rd, a -C(=O)ORd, or a -C(=O)NRfRg, wherein Rd, Re, Rf, and Rgare as defined in claim 6; wherein Ra, Rb, and s are as defined in claim 6; and Rhis as defined in the above.